Vivos Therapeutics issues going-concern warning
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Vivos Therapeutics, Inc. (VVOS) reported nine-month revenue of $16.708 million, versus $13.619 million a year earlier; third-quarter revenue was $6.414 million versus $6.783 million. Nine-month net loss was $15.245 million versus $14.276 million, while third-quarter net loss was $1.971 million versus $5.400 million, with $2.906 million in other income.
As of September 30, 2026, cash and equivalents were $247,000, and operating activities used $12.334 million over nine months. Vivos said its approximately $0.2 million cash balance would not fund operations and strategic objectives for the next 12 months; without additional financing, substantial doubt exists about its ability to continue as a going concern. Management said financing would be needed through the first quarter of 2027.
On August 4, 2026, Streeterville exchanged $3.25 million of debt for common and non-convertible preferred stock, which carries a 9% annual dividend. On September 2, 2026, Streeterville exchanged $2,861,270 of debt for 11,445,080 common shares at an average $0.25 per share; those shares represented about 34% of post-exchange outstanding common stock, and Vivos received no proceeds. Streeterville note principal was approximately $2.3 million as of September 30, 2026, due June 10, 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointNine-month revenue was $16.708 million, versus $13.619 million in 2025.
- Moderate pointThird-quarter net loss was $1.971 million, versus $5.400 million in 2025.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.Substantial doubt: approximately $0.2 million cash cannot fund the next 12 months.
- Moderate pointNine-month net loss was $15.245 million, versus $14.276 million in 2025.
- Moderate pointThird-quarter revenue was $6.414 million, versus $6.783 million in 2025.
- Moderate pointOperating cash used was $12.334 million, versus $11.451 million.
Filing Explained
The completed private placement creates an additional path to common-share issuance through preferred conversion and warrant exercise, separate from ATM shares already sold.
Form 10-Q is the unaudited quarterly report; this one says Vivos Therapeutics completed a private placement on
Separately, during the nine months ended
Key Figures
Key Terms
going concern financial
Employee Retention Credit financial
original issue discount financial
At-The-Market financial
Series B Non-Convertible Preferred Stock financial
beneficial ownership regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did VVOS report for the first nine months of 2026?
How many shares did VVOS issue to Streeterville in September 2026?
What terms apply to VVOS Series B preferred stock?
How much remained available under VVOS’s ATM program?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
| QUARTERLY report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 | |
| For the Quarterly
Period Ended | |
| or | |
| Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 | |
| For the Transition Period from to | |
Commission
File Number:
(Exact Name of Registrant as Specified in its Charter)
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
| (Address of principal executive offices) | (Zip Code) | |
| Registrant’s telephone number, including area code: |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of exchange on which registered | ||
Securities registered pursuant to Section 12(g) of the Act:
None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES ☐ NO ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YES ☐ NO ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES ☒ NO ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, or “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ |
| Smaller reporting company | |
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO
The
registrant had
TABLE OF CONTENTS
| Page | ||
| Cautionary Note Regarding Forward-Looking Statements | ii | |
| PART I. | FINANCIAL INFORMATION | 1 |
| Item 1. | Condensed Consolidated Financial Statements (Unaudited) | 1 |
| Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025 | 1 | |
| Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2026 and 2025 | 2 | |
| Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the three and nine months ended September 30, 2026 and 2025 | 3 | |
| Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025 | 4 | |
| Notes to the Condensed Consolidated Financial Statements | 5 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 26 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 36 |
| Item 4. | Controls and Procedures | 36 |
| PART II. | OTHER INFORMATION | 37 |
| Item 1. | Legal Proceedings | 37 |
| Item 1A. | Risk Factors | 37 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 44 |
| Item 3. | Defaults Upon Senior Securities | 44 |
| Item 4. | Mine Safety Disclosures | 44 |
| Item 5. | Other Information | 44 |
| Item 6. | Exhibits, Financial Statement Schedules | 44 |
| Signatures | 46 |
| i |
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q (this “Report”) contains “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) that reflect the Company’s current expectations and views of future events. The forward-looking statements are contained principally in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Readers are cautioned that known and unknown risks, uncertainties and other factors, including those over which the Company may have no control and others listed in this Report and the Company’s other public filings, may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements.
You can identify some of these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue,” “goal” or other similar expressions. The Company has based these forward-looking statements largely on its current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. These forward-looking statements include statements relating to:
| ● | the Company’s ability to continue to refine and execute the Company’s evolving business plan, including establishing and growing the Company’s new medical-provider focused sales, marketing and distribution model where the Company acquires or create contractual alliances with operators of sleep testing and treatment centers as a means of driving sales of the Company’s appliances, including the Company’s June 2025 acquisition of The Sleep Center of Nevada (“SCN”); | |
| ● | the Company’s ability to implement, generate material revenues from, and grow the Company’s medical-provider focused sales, marketing distribution model, which is new and unproven and may not produce the benefits the Company anticipates, and to fully wind down the Company’s legacy dentist-focused model; | |
| ● | the Company’s ability to successfully integrate SCN business into the Company’s operations, including managing staffing, accounting, insurance reimbursement and other challenges; | |
| ● | the Company’s ability to service the substantial indebtedness the Company incurred in connection with financing the SCN acquisition; | |
| ● | compliance with laws, rules and regulations relating to the corporate practice of medicine; | |
| ● | the acceptance and adoption by sleep specialists, medical doctors and other healthcare professionals of the Company’s proprietary oral appliances as a treatment for dentofacial abnormalities and/or mild to severe obstructive sleep apnea (“OSA”) and snoring in adults and moderate to severe OSA in children ages 6-17 as per the Company’s U.S. Food and Drug Administration (“FDA”) clearances, including the anticipated benefits of insurance coverage for products; | |
| ● | The Company’s ability to comply with the covenants in its financing agreements, including the requirements to keep the Company’s common stock listed om Nasdaq or another stock exchange; | |
| ● | the Company’s ability to realize the anticipated benefits of its October 2026 transaction (the “SOD Transaction”) with SOD Sciences, Inc. (“SOD”); | |
| ● | the dilution and other effects of the conversion of the 12,000 shares of Series C Convertible Preferred Stock the Company issued in the SOD Transaction (the “Series C Preferred”); | |
| ● | the Company’s accounting for the SOD Transaction, which has not been completed and remains subject to adjustment for twelve months after the closing; | |
| ● | the Company’s expectations concerning the effectiveness and duration of treatment using the Company’s appliances and protocols (which the Company refers to as The Vivos Method) and the potential for side effects including, but not limited to, patient relapse after completion of treatment; | |
| ● | the potential financial benefits to doctors, sleep testing centers, sleep specialists, and other healthcare professionals from treating patients with The Vivos Method; | |
| ● | the Company’s revenues, profit margin and cash flows based on sales or leasing of the Company’s appliances and other treatments and services, including the Company’s SleepImage® home sleep testing rings; | |
| ● | the Company’s ability to formulate, implement and modify as necessary effective sales, marketing and strategic initiatives to drive revenue growth (including, for example, the Company’s medical provider-focused strategic alliance and/or acquisition model, the Company’s SleepImage® home sleep apnea test and the Company’s other arrangements with sleep clinics and/or durable medical equipment companies (“DMEs”)); |
| ii |
| ● | the viability of the Company’s current intellectual property and the Company’s ability to create and protect new intellectual property in the future; | |
| ● | acceptance of the Company’s products and services by the medical and dental communities, as well as the marketplace of the products and services that the Company markets; | |
| ● | government regulations and the Company’s ability to obtain applicable regulatory approvals and comply with both state and federal government regulations including under healthcare laws and the rules and regulations of the FDA and non-U.S. equivalent regulatory bodies; | |
| ● | the Company’s ability to hire and retain key employees and other service providers (including dentists, medical doctors or other healthcare providers); | |
| ● | the emergence of alternative competing technologies, devices, drugs or other therapies which directly or indirectly impact the marketability of the Company’s products and services; | |
| ● | adverse changes in general market conditions for medical devices and the products and services the Company offers; | |
| ● | the Company’s ability to generate cash flow and profitability and continue as a going concern; | |
| ● | the Company’s ability to satisfy the criteria for maintaining the listing of the Company’s common stock on Nasdaq, including the $1.00 minimum closing bid price requirement, Nasdaq’s rule requiring a delisting determination and suspension of trading if the closing bid price is $0.10 or less for ten consecutive business days, the minimum stockholders’ equity requirement of $2.5 million and, if it takes effect, Nasdaq’s new minimum market value of listed securities requirement, which the Company has faced challenges with; | |
| ● | the Company’s immediate and future financing plans, including the Company’s ability to raise capital on acceptable terms or at all; and | |
| ● | the Company’s ability to adapt to changes in market conditions (including volatile and difficult to access capital markets) which could impair the Company’s operations and financial performance. |
These forward-looking statements involve numerous risks and uncertainties. Although the Company believes that its expectations expressed in these forward-looking statements are reasonable, the Company’s expectations may later be found to be incorrect. The Company’s actual results of operations or the results of other matters that the Company anticipates herein could be materially different from its expectations. Important risks and factors that could cause the Company’s actual results to be materially different from the Company’s expectations are generally set forth in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Business” and other sections in this Report as well as the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and the Company’s other public filings. You should thoroughly read this Report and the documents that the Company refers to with the understanding that its actual future results may be materially different from and worse than what the Company expects. The Company qualifies all of its forward-looking statements by these cautionary statements.
The forward-looking statements made in this Report relate only to events or information as of the date on which the statements are made in this Report. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this Report and the documents that the Company refers to in this Report and have filed as exhibits to this Report, completely and with the understanding that the Company’s actual future results may be materially different from what the Company expects.
| iii |
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements.
VIVOS THERAPEUTICS INC.
Unaudited Condensed Consolidated Balance Sheets
(In Thousands, Except Per Share Amounts)
| September 30, 2026 | December 31, 2025 | |||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Accounts receivable, net of allowance of $ | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Long-term assets | ||||||||
| Goodwill | ||||||||
| Property and equipment, net | ||||||||
| Operating lease right-of-use asset | ||||||||
| Intangible assets, net | ||||||||
| Deposits and other | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY/(DEFICIT) | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued expenses | ||||||||
| Contract liabilities | ||||||||
| Current portion of operating lease liability | ||||||||
| Current portion of financing lease liability | ||||||||
| Current portion of debt | ||||||||
| Other current liabilities | ||||||||
| Total current liabilities | ||||||||
| Long-term liabilities | ||||||||
| Employee retention credit liability | - | |||||||
| Operating lease liability, net of current portion | ||||||||
| Financing lease liability, net of current portion | ||||||||
| Debt, net of current portion | ||||||||
| Other liabilities | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies (Note 12) | - | - | ||||||
| Stockholders’ equity/(deficit) | ||||||||
| Preferred Stock, $ | $ | - | $ | - | ||||
| Preferred Stock – additional paid in capital | - | |||||||
| Common Stock, $ | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ equity/(deficit) | ( | ) | ||||||
| Non-controlling interest | ( | ) | ( | ) | ||||
| Total equity/(deficit) | ( | ) | ||||||
| Total liabilities and equity/(deficit) | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 1 |
VIVOS THERAPEUTICS INC.
Unaudited Condensed Consolidated Statements of Operations
(In Thousands, Except Per Share Amounts)
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | ||||||||||||||||
| Product revenue | $ | $ | $ | $ | ||||||||||||
| Service revenue | ||||||||||||||||
| Total revenue | ||||||||||||||||
| Cost of sales (exclusive of depreciation and amortization shown separately below) | ||||||||||||||||
| Gross profit | ||||||||||||||||
| Operating expenses | ||||||||||||||||
| General and administrative | ||||||||||||||||
| Sales and marketing | ||||||||||||||||
| Depreciation and amortization | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Operating loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Non-operating income (expense) | ||||||||||||||||
| Other expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income | ||||||||||||||||
| Loss before income taxes | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net loss attributable to non-controlling interest | ( | ) | - | ( | ) | - | ||||||||||
| Net loss attributable to stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net loss per share (basic and diluted) | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average number of shares of Common Stock outstanding (basic and diluted) | ||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 2 |
VIVOS THERAPEUTICS INC.
Unaudited Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
(In Thousands, Except Common Stock Amounts)
| Shares | Amount | Capital | Shares | Amount | Capital | Deficit | (Deficit) | interest | (Deficit) | |||||||||||||||||||||||||||||||
| Nine Months Ended September 30, 2026 and 2025 | ||||||||||||||||||||||||||||||||||||||||
| Preferred Stock | Preferred Additional Paid-in | Common Stock | Additional Paid-in | Accumulated | Total Stockholders’ Equity | Non-controlling | Total Equity |
|||||||||||||||||||||||||||||||||
| Shares | Amount | Capital | Shares | Amount | Capital | Deficit | (Deficit) | interest | (Deficit) | |||||||||||||||||||||||||||||||
| Balances, December 31, 2024 | - | $ | - | $ | - | $ | - | $ | $ | ( | ) | $ | $ | - | $ | |||||||||||||||||||||||||
| Stock-based compensation expense | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | - | ( |
) | |||||||||||||||||||||||||||
| Balances, March 31, 2025 | - | $ | - | $ | - | $ | - | $ | $ | ( | ) | $ | $ | - | $ | |||||||||||||||||||||||||
| Issuance of common stock and warrants in private placement, net of issuance costs | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||
| Common stock consideration for acquisition | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | - | ( |
) | |||||||||||||||||||||||||||
| Balances, June 30, 2025 | $ | - | $ | - | $ | - | $ | - | $ | $ | ( | ) | $ | $ | - | $ | ||||||||||||||||||||||||
| Issuance of common stock under At-The-Market program, net of issuance costs | $ | - | $ | - | $ | - | $ | $ | $ | - | $ | $ | - | $ | ||||||||||||||||||||||||||
| Issuance of common stock upon exercise of warrants, net of issuance costs | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | - | ( |
) | |||||||||||||||||||||||||||
| Balances, September 30, 2025 | $ | - | $ | - | $ | - | $ | $ | $ | ( | ) | $ | $ | - | $ | |||||||||||||||||||||||||
| Balances, December 31, 2025 | - | - | - | ( | ) | ( | ) | ( | ) | ( |
) | |||||||||||||||||||||||||||||
| Issuance of common stock under At-The-Market program, net of issuance costs | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||
| Issuance of common stock for consultants for services | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||
| Issuance of warrants in private placement, net of issuance costs | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Issuance of pre-funded warrants in private placement, net of issuance cost | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Issuance of common stock upon exercise of warrants, net of issuance costs | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||
| Conversion of debt to equity | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ( | ) | ( |
) | ||||||||||||||||||||||||||
| Balances, March 31, 2026 | - | $ | - | $ | - | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( |
) | |||||||||||||||||||||
| Issuance of common stock under At-The-Market program, net of issuance costs | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Issuance of preferred stock, net of issuance costs | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||
| Issuance of warrants in private placement, net of issuance costs | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||
| Issuance of common stock for consultants for services | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Conversion of debt to equity | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ( | ) | ( |
) | ||||||||||||||||||||||||||
| Balances, June 30, 2026 | $ | - | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( |
) | |||||||||||||||||||||||
| Issuance of preferred stock, net of issuance costs | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||
| Issuance of common stock in accordance with Exchange Agreement | - | - | ||||||||||||||||||||||||||||||||||||||
| Issuance of common stock under At-The-Market program, net of issuance costs | - | |||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for consultants for services | - | - | - | |||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | ||||||||||||||||||||||||||||||||||||||||
| Net loss | ( | ) | ( | ) | ( | ) | ( |
) | ||||||||||||||||||||||||||||||||
| Balances, September 30, 2026 | $ | - | $ | $ | $ | $ | ( | ) | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 3 |
VIVOS THERAPEUTICS INC.
Unaudited Condensed Consolidated Statements of Cash Flows
(In Thousands)
| 2026 | 2025 | |||||||
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Stock-based compensation expense | ||||||||
| Employee retention credit liability | ( | ) | - | |||||
| Non-cash interest expense on promissory note | - | |||||||
| Depreciation and amortization | ||||||||
| Fair value of common stock issued for services | - | |||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ( | ) | ( | ) | ||||
| Operating lease liabilities, net | ( | ) | ||||||
| Prepaid expenses and other current assets | ( | ) | ||||||
| Deposits and other | ( | ) | ||||||
| Accounts payable | ||||||||
| Accrued expenses | ||||||||
| Other liabilities | ||||||||
| Contract liability | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Payment for acquisition, net of cash acquired of $ | - | ( | ) | |||||
| Acquisitions of property and equipment | ( | ) | ( | ) | ||||
| Net cash used in investing activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from issuance of debt | ||||||||
| Proceeds from issuance of common stock | ||||||||
| Proceeds from issuance of preferred stock | - | |||||||
| Proceeds from issuance of warrants | ||||||||
| Proceeds from issuance of pre-funded warrants | ||||||||
| Proceeds from exercise of warrants | ||||||||
| Payments for issuance costs | - | ( | ) | |||||
| Reduction of debt liability | ( | ) | ( | ) | ||||
| Payments for finance lease liability | ( | ) | ( | ) | ||||
| Net cash provided by financing activities | ||||||||
| Net (decrease) increase in cash and cash equivalents | ( | ) | ( | ) | ||||
| Cash and cash equivalents at beginning of year | ||||||||
| Cash and cash equivalents at end of period | $ | $ | ||||||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||||||||
| Cash paid for interest | $ | $ | - | |||||
| SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||||||||
| Conversion of promissory note | $ | $ | ||||||
| Conversion of debt to common stock | $ | $ | - | |||||
Exchange of debt for common stock | $ | $ | - | |||||
Exchange of debt for Series B non-convertible preferred stock | $ | $ | - | |||||
| Common stock issued as consideration for acquisition | $ | - | $ | |||||
| Contingent consideration as consideration for acquisition | $ | - | $ | |||||
| Acquisitions of property, plant and equipment by issuing debt | $ | - | $ | |||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 4 |
VIVOS THERAPEUTICS INC.
Notes to Unaudited Condensed Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2026 and 2025
NOTE 1 - ORGANIZATION, DESCRIPTION AND SIGNIFICANT ACCOUNTING POLICIES
Organization
BioModeling Solutions, Inc. (“BioModeling”) was organized on March 20, 2007 as an Oregon limited liability company, and subsequently incorporated in 2013. On August 16, 2016, BioModeling entered into a share exchange agreement (the “SEA”) with First Vivos, Inc. (“First Vivos”), and Vivos Therapeutics, Inc. (“Vivos”), a Wyoming corporation established on July 7, 2016 to facilitate the SEA transaction. Vivos was formerly named Corrective BioTechnologies, Inc. until its name changed on September 6, 2016 to Vivos Biotechnologies and on March 2, 2018 to Vivos Therapeutics, Inc. and had no substantial pre-combination business activities. First Vivos was incorporated in Texas on November 10, 2015. Pursuant to the SEA, all of the outstanding shares of common stock and warrants of BioModeling and all of the shares of common stock of First Vivos were exchanged for newly issued shares of common stock and warrants of Vivos, the legal acquirer.
The transaction was accounted for as a reverse acquisition and recapitalization, with BioModeling as the acquirer for financial reporting and accounting purposes. Upon the consummation of the merger, the historical financial statements of BioModeling became the Company’s historical financial statements and recorded at their historical carrying amounts.
On
August 12, 2020, Vivos reincorporated from Wyoming to become a domestic Delaware corporation under Delaware General Corporate Law. Accordingly,
as used herein, the term “the Company” refers to Vivos Therapeutics, Inc., a Delaware corporation and its consolidated subsidiaries.
As used herein, the term “Common Stock” refers to the common stock, $
On
June 10, 2025, the Company acquired all of the operating assets (the “Acquisition”) of R.D. Prabhu-Lata K. Shete MDs, LTD.,
a Nevada professional corporation d/b/a The Sleep Center of Nevada (“SCN”) in consideration for a (i) cash payment equal
to $
On
July 14, 2025, the Company entered into a management agreement with MISleep Solution LLC to provide full suite of Vivos treatments and
services to OSA patients at a joint location in Auburn Hills, Michigan. As a result, the Company formed AIM Detroit, LLC, a Colorado
limited liability company (“AIM Detroit”) to serve as a management services organization to medical and dental clinical sleep
practices located in the Detroit Tri-County metropolitan area, to wit: Wayne County, Oakland County and Macomb County. The Company holds
an
On June 10, 2026, the Company entered into a collaboration agreement with South Palm Cardiovascular Associates, LLC (SPCVA) to establish and operate a Sleep and Airway Medicine Center (SAMC) in a location (to be determined) near one of the firm’s four locations in Del Ray Beach, Boynton Beach, Boca Raton, and West Palm Beach, Florida. The intent of the agreement is to bring much needed sleep testing and treatment to SPCVA’s estimated patient population of over 31,000 patients. The business model will be patterned after the Company’s successful SAMC model pioneered in Las Vegas, Nevada in connection with the Sleep Center of Nevada acquisition. Operations are expected to begin in early 2027. The collaboration agreement contemplates a fair market value financial investment by SPCVA into the management services operating entity (the MSO) that will run the SAMC operation with a proportionate participation in net income (if any) earned by the MSO.
Description of Business
The Company is a medical technology and healthcare services company that features a comprehensive suite of proprietary oral appliances and therapeutic treatments for a variety of sleep disorders. The Company’s products non-surgically treat certain maxillofacial and developmental abnormalities of the mouth and jaws that are closely associated with breathing and sleep disorders such as, mild to severe obstructive sleep apnea (“OSA”) and snoring in adults. The Company currently operates seven sleep testing centers (Sleep Center of Nevada or SCN) that it acquired in June of 2025 from Dr. Prabhu Rachakonda, MD. That acquisition was part of a strategic pivot away from a reliance on dentists and independent dental practices and toward a focus on affiliations with sleep specialty practices and other medical practices where large numbers of patients with sleep disorders and related conditions may be found.
In connection with that acquisition, Vivos established two treatment centers it calls Sleep and Airway Medicine Centers (SAMC). SAMC centers take in patients who have tested positive for OSA, insomnia, or other sleep disorders and offer them a full spectrum of treatment options, including CPAP, advanced laser therapy, Vivos mandibular advancement devices, Vivos CARE devices, and other adjunctive treatments such as myofunctional therapy. The SAMC offices operate under a management services organization model that manages and supports both medical and dental professionals in their respective and independent professional entities. The Company has taken several precautions to ensure that the business entity and legal structure is compliant with both state and federal laws and regulations that govern such relationships. Under such regulations, licensed healthcare providers may participate in ownership of the management services company as long as they are not compensated for referrals or in any manner that is tied to referrals or other volume based incentives.
| 5 |
In addition to the SCN and SAMC offices in Nevada, the Company intends to pursue similar affiliations with medical practices in other areas, and has already executed affiliation agreements in Detroit, Michigan and South Florida. Concurrently, Vivos continues to offer separate training and clinical pathways or programs to independent dental providers who wish to learn more about Vivos products and services. Such training programs include: (i) Lifeline (focused on basic dental airway management and principles of mandibular advancement devices and other adjunctive services, and (ii) Complete Airway Repositioning and Expansion (“C.A.R.E.”). Each program features certain oral appliances coupled with specific therapeutic treatments, and each clinical pathway is intended to address the specific needs of a diverse patient population with different patient journeys. For example, the Lifeline program features training in the use of CO2 laser treatments and other adjunctive and a selection of mandibular advancement devices (“MADs”) such as the Versa and Vida Sleep which are U.S. Food and Drug Administration (“FDA”) 510(k) cleared for mild-to-moderate OSA in adults, along with the patented Vida appliance, which is FDA 510(k) cleared as unspecified classification for the alleviation of Temporomandibular Joint Dysfunction (“TMD”) symptoms, bruxism, migraine headaches, and nasal dilation.
The
Company’s flagship C.A.R.E. program, which is part of The Vivos Method, features the Company’s patented DNA, mRNA and mmRNA
appliances, which are also FDA 510(k) cleared for mild-to-severe OSA and snoring in adults. The Vivos Method may also include adjunctive
myofunctional, chiropractic/physical therapy, and laser treatments that, when properly used with the C.A.R.E. appliances, constitute
a powerful non-invasive and cost-effective means of reducing or eliminating OSA symptoms. In a small subset of a study, the data has
actually shown that The Vivos Method can reverse OSA symptoms in a large portion (up to
Although not the Company’s current focus due to the pivot in the business model, the Company has historically offered a suite of diagnostic and support products and services to dental and medical providers and distributors who service patients with OSA or related conditions. Such products and services include (i) VivoScore home sleep screenings and tests (powered by SleepImage® technology), (ii) Treatment Navigator (a concierge service to assist a provider in educating and supporting the doctors as they navigate insurance coverage, diagnostic indications and treatment options), (iii) Billing Intelligence Services (which optimizes medical and dental reimbursement), (iv) advanced training and continuing education courses at the Company’s Vivos Institute in Denver, Colorado, and (v) MyoSync (formerly MyoCorrect), a service through which Vivos-trained providers can provide orofacial myofunctional therapy (“OMT”) to patients via a telemedicine platform. Some of these services including home sleep screenings, treatment navigator services and MyoSync are being provided to patients directly under the new sales, marketing and distribution model described below. With this pivot, the Company shifted its Medical Integration Division (“MID”) to pursue strategic alliances and acquisitions of sleep centers to provide better options using Vivos products for patients who have been diagnosed with OSA.
Legacy Business Model
Prior to 2024, the Company’s business model was to teach, train, and support dentists, medical doctors, and distributors in the use of the Company’s products and services. Dentists who use the Company’s products and services typically enrolled in a variety of live or online training and educational programs offered through the Company’s Vivos Institute; an 18,000 sq. ft. facility located near the Denver International Airport. Dentists were able to select the specific program or clinical pathway that they want to focus on, such as Guided Growth and Development or Lifeline or both. They could also enroll in the Company’s Vivos Integrated Provider (“VIP”) program for the complete set training, educational, and support services available in all three clinical pathway programs. Since 2024, Vivos has phased out and discontinued offering the VIP program, although it continues to offer training and continuing education courses on a more limited basis for Lifeline and CARE product lines. The Company refers to the former VIP-focused business model as the Company’s “legacy” or “historic” business model.
New Sales, Marketing and Distribution Model
Over the course of 2024 and during 2025, the Company worked to pivot its business strategy and began to steadily decrease the Company’s prior dependence on dentists to sell the Company’s products and the Company’s dependence on VIP enrollment revenue. This new business strategy is focused on contractual alliances with and outright acquisitions of medical sleep specialty providers, sleep centers and other medical specialty practices and is based on a profit-sharing model between the Company and the provider which aligns the Company’s revenue generation more directly to sales of the Company’s novel appliances.
| 6 |
In June 2025, the Company acquired all assets, including operating assets such as sleep testing, diagnostics, and treatment centers of SCN. The Acquisition marked a milestone in the pivot to the Company’s sales, marketing and distribution model for the Company’s innovative OSA appliances. Under the new model, SCN will provide sleep disorder patients with the opportunity to be candidates for the Company’s advanced, proprietary and FDA-cleared CARE oral medical devices, oral appliances and additional adjunctive therapies and methods. Under customary agreements designed to comply with applicable corporate practice of medicine law, the Company’s operation of SCN allows the Company to manage and capture both diagnostic and consulting revenues, representing new higher margin revenue streams for the Company, as well as potential Vivos appliance and related product and service revenue from SCN.
On July 14, 2025, the Company entered into a management agreement under this revised approach with MISleep Solution LLC to provide full suite of Vivos treatments and services to OSA patients at a joint location in Auburn Hills, Michigan. Consistent with the Company’s new model, the Company owns a supermajority equity stake in the management services company, with the sleep doctors having minority ownership interests. AIM Detroit entered into Practice Administration Agreements and Management and Succession Agreements with affiliated Practices (defined as the professional medical and dental practice entities, including Sleep Dentistry of Detroit, P.C. and Sleep Medicine of Detroit, P.C., each owned and controlled by their respective licensed professionals) under which AIM Detroit provides business, administrative, and other non-clinical management services, while all clinical and professional services remain exclusively under the authority and control of the Practices and their licensed professionals.
On June 10, 2026, Vivos entered into a collaboration and services agreement with South Palm Cardiovascular Associates (SPCVA) in order to establish and operate a SAMC center near any of four separate SPCVA office locations in South Florida. Under the collaboration and services agreement, SPCVA will invest directly in the management services entity that will manage the licensed professional entities for both medical and dental practitioners at the SAMC location. The model being employed in South Florda with SPCVA is expected to become the primary operating model as the Company scales up and into multiple additional markets going forward.
The Company is exploring and seeking to implement additional acquisitions of, or collaborations with, medical sleep and similar healthcare practices to expand the Company’s business model in an effort to grow the Company’s revenues.
The Company refers to this new model herein alternatively as its new sales, marketing and distribution model or the Company’s strategic alliance and/or acquisition model.
Basis of Presentation and Consolidation
The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with current United States generally accepted accounting principles (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company’s financial position, results of operations, and cash flows. The condensed consolidated balance sheet at December 31, 2025 has been derived from audited financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (“SEC”).
The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the December 31, 2025 audited consolidated financial statements contained in the Company’s 2025 Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on April 15, 2026.
The Company evaluates its interests in legal entities to determine whether such entities should be consolidated under the voting interest entity model or the variable interest entity (“VIE”) model. When the Company determines that it is the primary beneficiary of a VIE, the Company consolidates the entity and includes its assets, liabilities, revenues, and expenses in the consolidated financial statements. Ownership interests not held by Vivos are reflected as noncontrolling interests within equity. All significant intercompany balances and transactions have been eliminated in consolidation. See Note 17 for additional information regarding Vivos’ involvement with AIM Detroit.
| 7 |
Purchase Price Allocation
The Company accounts for business combinations in accordance with ASC Topic 805, Business Combinations, which requires the assets acquired and liabilities assumed in business combinations based on their estimated fair values at the date of acquisition, which involves a number of assumptions, estimates, and judgments, which are inherently uncertain and subject to refinement. The Company determines the estimated fair values with the assistance of valuations performed by third party specialists, discounted cash flow analysis, and estimates made by management derived from comparable market data and cash flow projections used to value the acquired business. The Company’s ability to realize the future cash flows used in the Company’s fair value estimates may be affected by changes in the Company’s financial condition, financial performance, or business strategies. The Company’s assumptions and estimates are also used to allocate goodwill to the Company’s reporting units that are expected to benefit from the business combination.
Emerging Growth Company Status
Effective December 31, 2025, the Company was no longer an “emerging growth company” (an “EGC”), as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). As a result, the Company has lost some of the benefits of being an EGC, although the Company remains a “smaller reporting company” and therefore can avoid the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”).
Use of Estimates
The preparation of financial statements and related disclosures in conformity with GAAP requires the Company to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. The Company bases its estimates and assumptions on existing facts, historical experience, and various other factors that the Company believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company’s significant accounting estimates include, but are not necessarily limited to, assessing collectability on accounts receivable, determining customer life and breakage related to recognizing revenue for VIP contracts, impairment of goodwill and long-lived assets; valuation assumptions for assets acquired in asset acquisitions and business combinations; valuation assumptions for stock options, warrants, warrant liabilities and equity instruments issued for goods or services; deferred income taxes and the related valuation allowances; the evaluation and measurement of contingencies; and the derecognition of the Company’s employee retention credit liability. The Company believes the Company has made appropriate accounting estimates based on the facts and circumstances available as of the reporting date. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future consolidated results of operations will be affected.
Accounting Pronouncements
Presented below is a discussion of new accounting standards including deadlines for adoption.
Recent Accounting Pronouncements Yet to be Adopted
In November 2024, the FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses (“ASU 2024-03”). The standard’s purpose is “to improve the disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&A, and research and development).” Public companies will be required to disclose in the notes to financial statements specified information about certain costs and expenses at each interim and annual reporting period. Specifically, they will be required to:
| 1. | Disclose the amounts of (a) purchases of inventory; (b) employee compensation; (c) depreciation; (d) intangible asset amortization; and (e) depreciation, depletion, and amortization recognized as part of oil- and gas-producing activities (or other amounts of depletion expense) included in each relevant expense caption. |
| 8 |
| 2. | Include certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements. |
| 3. | Disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively. | |
| 4. | Disclose the total amount of selling expenses and, in annual reporting periods, an entity’s definition of selling expenses. |
The amendments in the ASU are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the effect of this new guidance on its consolidated financial statements and disclosures.
In September 2025, the FASB issued ASU 2025-06, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (“ASU 2025-06”), which updates the accounting for internal-use software by removing project stage references and introduces a new capitalization threshold based on management authorization and project completion probability. The guidance requires evaluation of significant development uncertainty, including novel functionality and unresolved performance requirements. ASU 2025-06 also requires website-specific development costs to be evaluated under the same framework as other internal-use software and clarifies that capitalized internal-use software costs are subject to the property, plant and equipment disclosure requirements under ASC 360-10. The amendments in the ASU are effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years. Early adoption permitted. The Company is currently evaluating the impact of ASU 2025-06 on the Company’s consolidated financial statements and disclosures.
The Company has reviewed and considered all other recent accounting pronouncements that have not yet been adopted and believe there are none that could potentially have a material impact on the Company’s business practices, financial condition, results of operations, or disclosures.
NOTE 2 - LIQUIDITY AND ABILITY TO CONTINUE AS A GOING CONCERN
The
financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of
the Company as a going concern. The Company has incurred losses since inception, including $
Net
cash used in operating activities amounted to approximately $
As
of September 30, 2026, the Company had approximately $
As of September 30, 2026, the Company had approximately $
The Company has implemented cost savings measures that lead to reduced impact to cash used in operations. Sales grew in the financial year ended December 31, 2025 and the first nine months of 2026 as anticipated as the Company continued to refine its product offerings and strategies. As such, notwithstanding that the Company has raised equity capital throughout the fiscal year ended December 31, 2025 and through the first three quarters of 2026, the Company will be required to obtain additional financing through the first quarter of 2027 to satisfy the cash needs for the Company’s business and bolster the Company’s stockholders’ equity for Nasdaq compliance purposes, as management continues to work towards increasing revenue to achieve cash flow positive operations in the foreseeable future
| 9 |
The Company does not have any off-balance sheet arrangements, as defined by applicable regulations of the SEC, that are reasonably likely to have a current or future material effect on the Company’s financial condition, results of operations, liquidity, capital expenditures or capital resources.
NOTE 3 - REVENUE, CONTRACT ASSETS AND CONTRACT LIABILITIES
Net Revenue
For the three and nine months ended September 30, 2026 and 2025, the components of revenue from contracts with customers and the related timing of revenue recognition is set forth in the table below (in thousands):
SCHEDULE OF REVENUE FROM CONTRACT WITH CUSTOMERS
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Product revenue | ||||||||||||||||
| Appliances | $ | $ | $ | $ | ||||||||||||
| Tooth Positioners | ||||||||||||||||
| Total product revenue | (1) | (1) | (1) | (1) | ||||||||||||
| Service revenue | ||||||||||||||||
| Sleep testing services | $ | (3) | $ | (3) | $ | (3) | $ | (3) | ||||||||
| Treatment centers | (2) | (2) | (2) | (2) | ||||||||||||
| VIP | - | (2) | (2) | (2) | (2) | |||||||||||
| Billing intelligence services | (3) | (3) | (3) | (3) | ||||||||||||
| Myofunctional therapy services | (2) | (2) | (2) | (2) | ||||||||||||
| Sponsorship/seminar/other | (3) | (3) | (3) | (3) | ||||||||||||
| Total service revenue | ||||||||||||||||
| Total revenue | $ | $ | $ | $ | ||||||||||||
| (1) | |
| (2) | |
| (3) |
| 10 |
Changes in Contract Liabilities
The key components of changes in contract liabilities related to the Company’s legacy model for the nine months ended September 30, 2026 and 2025 are as follows (in thousands):
SCHEDULE OF CHANGES IN CONTRACT LIABILITIES
| 2026 | 2025 | |||||||
| Beginning balance, January 1 | $ | $ | ||||||
| New contracts, net of cancellations | ||||||||
| Revenue recognized | ( | ) | ( | ) | ||||
| Ending balance, September 30 | $ | $ | ||||||
The
current portion of deferred revenue is approximately $
Changes in Accounts Receivable
The
Company’s customers are billed based on fees agreed upon in each customer contract. Receivables from customers, which are stated
at the net amount expected to be collected, were $
NOTE 4 - PROPERTY AND EQUIPMENT, NET
As of September 30, 2026 and December 31, 2025, property and equipment consist of the following (in thousands):
SCHEDULE OF PROPERTY AND EQUIPMENT
September 30, 2026 | December 31, 2025 | |||||||
| Furniture and equipment | $ | $ | ||||||
| Leasehold improvements | ||||||||
| Molds and other | ||||||||
| Gross property and equipment | ||||||||
| Less accumulated depreciation | ( | ) | ( | ) | ||||
| Net Property and equipment | $ | $ | ||||||
Leasehold
improvements relate to the Vivos Institute (a
NOTE 5 - GOODWILL AND INTANGIBLE ASSETS
Goodwill
Goodwill
of $
SCHEDULE OF GOODWILL
| Acquisitions | September 30, 2026 | December 31, 2025 | ||||||
| The Sleep Center of Nevada | $ | $ | ||||||
| BioModeling | ||||||||
| Empowered Dental | ||||||||
| Lyon Dental | ||||||||
| Total goodwill | $ | $ | ||||||
| 11 |
Intangible Assets
Intangible
assets consist of assets acquired from First Vivos and costs paid to (i) MyoSync, from whom the Company acquired certain assets related
to its OMT service in March 2021, (ii) Lyon Dental, from whom the Company acquired certain medical billing and practice management software,
licenses and contracts in April 2021 (including the software underlying AireO2) for work related the Company’s acquired patents,
intellectual property and customer contracts and (iii) AFD, from whom the Company acquired certain U.S. and international patents, trademarks,
product rights, and other miscellaneous intellectual property in March 2023, and (iv) SCN, from whom the Company acquired tradenames
and referral relationships. Internal-use software of $
The
identifiable intangible assets acquired from First Vivos and Lyon Dental for customer contracts are amortized using the straight-line
method over the estimated life of the assets, which approximates
As of September 30, 2026, and December 31, 2025, identifiable intangible assets were as follows (in thousands):
SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS
September 30, 2026 | December 31, 2025 | |||||||
| Patents and developed technology | $ | $ | ||||||
| Internal-use software | ||||||||
| Trade name | ||||||||
| Other | ||||||||
| Total intangible assets | ||||||||
| Less accumulated amortization | ( | ) | ( | ) | ||||
| Net intangible assets | $ | $ | ||||||
Amortization
expense of identifiable intangible assets was $
SCHEDULE OF ESTIMATED FUTURE AMORTIZATION OF IDENTIFIABLE ASSETS
| Years Ending December 31, | ||||
| 2026 (remaining three months) | ||||
| 2027 | ||||
| 2028 | ||||
| 2029 | ||||
| 2030 | ||||
| Thereafter | ||||
| Total | $ | |||
| 12 |
NOTE 6 – OTHER FINANCIAL INFORMATION
Accrued Expenses
As of September 30, 2026 and December 31, 2025, accrued expenses consist of the following (in thousands):
SCHEDULE OF ACCRUED EXPENSES
| September 30, 2026 |
December 31, 2025 |
|||||||
| Accrued payroll | $ | $ | ||||||
| Accrued interest expense | ||||||||
| Accrued royalties | ||||||||
| Accrued sales tax | ||||||||
| Accrued legal and other | ||||||||
| Total accrued liabilities | $ | $ | ||||||
NOTE 7 – DEBT AND OTHER LIABILITIES
Debt
The Company had the following outstanding Note Payable balance as of September 30, 2026 and December 31, 2025, excluding equipment financing:
SCHEDULE OF OUTSTANDING NOTE PAYABLE BALANCE
| September 30, 2026 | December 31, 2025 | |||||||
| Principal amount | $ | $ | ||||||
| Less: Unamortized debt issuance costs and original issue discount | ( | ) | ( | ) | ||||
| Total notes payable | $ | $ | ||||||
On
June 9, 2025, the Company entered into a note purchase agreement with Streeterville Capital, LLC (“Streeterville” or the “Lender”) secured by the assets of Airway Integrated Management Company,
LLC, a Colorado limited liability company and a wholly-owned subsidiary of the Company (“AIM”), pursuant to which the Company
agreed to issue and sell to the Lender a secured promissory note (the “Note”) in an aggregate initial principal amount of $
Interest
on the Note accrues at a rate of
Beginning
on the sixth month anniversary of the issuance, which was December 9, 2025, the Lender shall have the right to redeem up to $
In connection with the
Exchange Agreement described in Note 9, the Note was amended by an Amendment to Secured Promissory Note dated June 5, 2026, as
modified by a letter agreement dated June 18, 2026. Because the Company completed the qualifying equity financing in August 2026,
the maturity date of the Note was extended to
| 13 |
On
December 5, 2025, the Company entered into a Note Purchase Agreement with Avondale Capital, LLC, a Utah limited liability company (“Avondale”),
pursuant to which the Company issued and sold to Avondale a Promissory Note in the original principal amount of $
The
Avondale Note does not bear interest and no interest will accrue on the Avondale Note unless an event of default occurs as further described
below. The Company has made weekly payments of approximately $
The Avondale Note is unsecured. In connection with the Avondale Note Financing, the Company has caused Company’s wholly-owned subsidiary, AIM to enter into the Guaranty Agreement, dated December 5, 2025, in favor of Avondale to provide a guarantee of the Company’s obligations to Avondale under the Avondale Note and the other transaction documents.
During the third quarter 2026, the Company entered into several short-term
agreements, collateralized by a portion of its accounts receivable, for approximately $
Equipment Financing
At September 30, 2026 and December 31, 2025, the Company had the following outstanding notes payable for equipment financing as follows (in thousands):
SCHEDULE OF OUTSTANDING NOTES PAYABLE FOR EQUIPMENT FINANCING
| September 30, 2026 | December 31, 2025 | |||||||
| Principal amount | $ | $ | ||||||
| Total | $ | $ | ||||||
The maturity of notes payable for equipment financing is as follows (in thousands):
SCHEDULE OF AMORTIZATION OF NOTES PAYABLE
| Years Ending December 31, | ||||
| 2026 (remaining three months) | $ | |||
| 2027 | ||||
| 2028 | ||||
| 2029 | ||||
| 2030 | ||||
| Thereafter | ||||
| Total | $ | |||
Interest
expense recognized on the condensed consolidated statement of operations was $
| 14 |
Other Liabilities
As of September 30, 2026 and December 31, 2025, other liabilities consist of the following (in thousands):
SCHEDULE OF OTHER LIABILITIES
| September 30, 2026 |
December 31, 2025 |
|||||||
| Contingent consideration on acquisition of SCN | $ | $ | ||||||
| Total | $ | $ | ||||||
The
fair value of the contingent consideration was determined using a Monte Carlo simulation of potential outcomes. The contingent consideration
is payable in the form of restricted Common Stock equal to $
This
contingent consideration liability is recognized as a liability due to the variability of the potential share settlement and will be
remeasured at fair value each reporting period until the contingency is resolved, with changes in fair value recognized in operating
expenses. During the three and nine months ended September 30, 2026, the Company recognized a gain in other income for the change in
fair value of contingent consideration of approximately $
Employee Retention Credit
During
the period, management reassessed the Company’s potential obligation to repay amounts previously received under the Employee Retention
Credit (“ERC”) program established by the Coronavirus Aid, Relief, and Economic Security Act. Based on its evaluation of the
Company’s eligibility for the credits, applicable guidance, and other relevant facts and circumstances, management concluded that repayment
of the credits is no longer deemed probable. Accordingly, the Company reversed its previously recorded ERC liability of approximately
$
The Company acknowledges that ERC claims remain subject to potential examination by the Internal Revenue Service.
NOTE 8 – PREFERRED STOCK
As
of September 30, 2026, the Company’s Board of Directors continues to have the authority to designate up to
June 2026 PIPE Offering and Conversion of V-CO 4 Bridge Note
On June 30, 2026, the Company entered into a Securities Purchase Agreement (the “PIPE SPA”) with V-Co 4 and Bigger Capital Fund, LP (“Bigger” and collectively, the “Investors”).
Pursuant
to the PIPE SPA, the Company sold an aggregate of
The
$
| 15 |
NOTE 9 – COMMON STOCK
The
Company is authorized to issue
The following is a description of Common Stock transactions since December 31, 2025:
January 2026 Warrant Inducement Transaction
On
January 15, 2026, the Company entered into a warrant inducement letter agreement (the “January 2026 Inducement Agreement”)
with an institutional investor (the “Holder”), pursuant to which the Holder agreed to exercise for cash the entirety of its
January 2023 Warrants, November 2023 Series A Warrants and February 2024 Inducement Warrants at a reduced exercise price of $
January 2026 V-CO Investors 3 LLC Note
On
January 15, 2026, the Company entered into an unsecured convertible promissory note in favor of V-CO Investors 3 LLC (“V-CO 3”)
in the maximum principal amount of up to $
The
purpose of the V-CO 3 Note is to provide advanced funding and support to the Company in connection with a proposed equity financing of
the Company in the aggregate amount of up to $
On
January 15, 2026 and March 26, 2026, V-CO funded an initial $
The
V-CO 3 Note does not bear any interest, except in the case of an event of default, which is defined as
In the event of a Subsequent Financing prior to the Outside Date, all principal under the V-CO 3 Note shall automatically convert dollar-to-dollar, without any further action required on the part of V-CO or the Company, into such equity instruments of the Company as are issued in the Subsequent Financing. The Subsequent Financing may, but is not required to be, led by V-CO. Following the Outside Date, the Company may repay all or any portion of the outstanding principal amount and any accrued interest of the V-CO 3 Note in whole or in part without penalty.
On
March 31, 2026, the Company entered into an equity financing with V-CO 3 and accordingly, $
| 16 |
March 2026 PIPE Offering
On March 31, 2026, the Company entered into a Securities Purchase Agreement (the “March 2026 PIPE SPA”) with V-CO 3.
Pursuant
to the March 2026 PIPE SPA, the Company sold to V-CO 3 in a private placement offering (the “March 2026 PIPE Offering”):
(i)
V-CO
3 paid a purchase price of $
Both
March 2026 Common Stock Purchase Warrants have an exercise price of $
The terms of the March 2026 PIPE SPA require the Company to file a registration statement on Form S-3 or other appropriate form registering the March 2026 PIPE Shares, the March 2026 PFW Shares and the March 2026 Warrant Shares (collectively, the “March 2026 Registrable Securities”) for resale no later than 45 days of the closing of the March 2026 PIPE Offering and to use commercially reasonable best efforts to cause such resale registration statement to be effective within 90 days of the closing of the March 2026 PIPE Offering. The Company must also use its commercially reasonable efforts to keep such resale registration statement continuously effective (including by filing a post-effective amendment to such resale registration statement or a new registration statement if such resale registration statement expires) for a period of three (3) years after the date of effectiveness of such resale registration statement or for such shorter period as such securities no longer constitute March 2026 Registrable Securities, subject to certain limitations specified in the March 2026 PIPE SPA.
The
March 2026 PIPE SPA further provides that the Company shall pay V-CO 3 in the amount equal to $
| 17 |
Streeterville Exchange Agreement
On
June 5, 2026, the Company entered into an Exchange Agreement (the “Exchange Agreement”) with Streeterville Capital, LLC
pursuant to which Streeterville agreed to exchange up to approximately $
On
August 4, 2026, the Company exceeded the financing requirement, which triggered the exchange of a total of $
Additionally, effective
August 31, 2026, the Company entered into twelve separate exchange agreements with Streeterville, pursuant to which an aggregate of
$
On October 16, 2026, Streeterville
provided its consent, pursuant to the Company’s existing financing arrangements, to the issuance of
“At-the-Market” Equity Offering
As previously reported on a Current Report on Form 8-K filed on February 14, 2025 (the “February 8-K”), on February 14, 2025, pursuant to a prospectus supplement to the Company’s previously filed shelf registration statement on Form S-3 (File No. 333-262554) (the “Prior Shelf Registration”), the Company entered into an At The Market Offering Agreement (the “ATM Sales Agreement”) with HCW, pursuant to which the Company may offer and sell shares of Common Stock from time to time through HCW. The Company did not sell any shares of Common Stock under the Prior Shelf Registration pursuant to the ATM Sales Agreement.
On
September 12, 2025, the Company filed a prospectus supplement (the “ATM Pro Supp”) with the SEC pursuant to which the Company
may continue, under the ATM Sales Agreement, to sell, from time to time, up to an aggregate sales price of $
The offer and sale of the ATM Shares have been made pursuant to a shelf registration statement on Form S-3 (File No. 333-284834), as amended (the “New Shelf Registration”), initially filed by the Company with the SEC on February 11, 2025 and declared effective by the SEC on September 10, 2025, as supplemented by the ATM Pro Supp filed with the SEC pursuant to Rule 424(b) under the Securities Act.
During
the nine months ended September 30, 2026, the Company sold an aggregate of
As of September 30, 2026 and December 31, 2025, all warrants outstanding have been classified as equity and recorded at fair values of the date of issuance on the Company’s consolidated balance sheets and there have been no further adjustments to their issuance date valuation. To better ascertain the nature of the equity, ASC 815, Derivatives and Hedging and ASC 480, Distinguishing Liabilities from Equity were referenced.
NOTE 10 – STOCK OPTIONS AND WARRANTS
Stock Options
On
November 26, 2024, the Company’s shareholders approved and adopted the Vivos Therapeutics, Inc. 2024 Omnibus Equity Incentive Plan
(or the “2024 Omnibus Plan”). The 2024 Omnibus Plan automatically replaced and superseded the 2019 Plan. Under the 2024 Omnibus
Plan, a total of
| 18 |
The
purpose of the 2024 Omnibus Plan is to promote the success and enhance the value of the Company by linking the personal interest of the
participants to those of the Company’s stockholders by providing the participants with an incentive for outstanding performance.
Any non-employee director, officer, employee or consultant of the Company or its subsidiaries or affiliates will be eligible to participate
in the 2024 Omnibus Plan. As of September 30, 2026, the Company had six non-employee directors, two officers, 242 employees and four
consultants, although the Company expects that, based on the Company’s current usage, award will be generally limited to approximately
six non-employee directors, two officers, twelve employees, and three consultants. The 2024 Omnibus Plan provides for the grant of options
to purchase shares of the Company’s Common Stock, including stock options intended to qualify as incentive stock options (“ISOs”)
under Section 422 of the Code and nonqualified stock options that are not intended to so qualify (“NQSOs”), stock appreciation
rights (“SARs”), restricted stock awards, and other equity-based or equity-related awards including restricted stock units
and performance units (each, an “Award”). As of September 30, 2026, awards (in the form of options, stock grants, performance
stock units (“PSUs”) and restricted stock units (“RSU”) for an aggregate of
The following table summarizes all stock options as of September 30, 2026 (shares in thousands):
SCHEDULE OF STOCK OPTIONS
| 2026 | ||||||||||||
| Shares | Price (1) | Term (2) | ||||||||||
| Outstanding, at December 31, 2025 | $ | |||||||||||
| Granted | ||||||||||||
| Forfeited | ( | ) | ||||||||||
| Exercised | - | |||||||||||
| Outstanding, at September 30 2026 | (3) | $ | ||||||||||
| Exercisable, at September 30 2026 | (4) | $ | ||||||||||
| (1) | |
| (2) | |
| (3) | |
| (4) |
There
were
Unrecognized
expense relating to these awards as of September 30, 2026 and 2025 was approximately $
| 19 |
Restricted Stock Units
The following table summarizes all RSUs as of September 30, 2026 (shares in thousands):
SCHEDULE OF RSU GRANTED
| 2026 | ||||||||||||
| Shares | Price (1) | Term (2) | ||||||||||
| Outstanding, at December 31, 2025 | $ | |||||||||||
| Granted | ||||||||||||
| Forfeited | - | - | ||||||||||
| Exercised | - | - | ||||||||||
| Outstanding, at September 30 2026 | (3) | $ | ||||||||||
| Exercisable, at September 30 2026 | (4) | $ | ||||||||||
| (1) | |
| (2) | |
| (3) | |
| (4) |
Warrants
The following table sets forth activity with respect to the Company’s warrants to purchase Common Stock for the nine months ended September 30, 2026 (shares in thousands):
SCHEDULE OF WARRANT OUTSTANDING
| 2026 | ||||||||||||
| Shares | Price (1) | Term (2) | ||||||||||
| Outstanding, at December 31, 2025 | $ | |||||||||||
| Granted | ||||||||||||
| Private placement | ||||||||||||
| Warrant Inducement | ||||||||||||
| Forfeited | ( | ) | - | |||||||||
| Exercised | ( | ) | - | |||||||||
| Outstanding, at September 30, | (3) | $ | ||||||||||
| Exercisable, at September 30, | (4) | |||||||||||
| (1) | |
| (2) | |
| (3) | |
| (4) |
For the nine months ended September 30, 2026, the valuation assumptions for warrants issued were estimated on the measurement date using the BSM option-pricing model with the following weighted-average assumptions:
SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS USED IN THE FAIR VALUE
| 2026 | ||||
| Measurement date closing price of Common Stock (1) | $ | |||
| Contractual term (years) (2) | ||||
| Risk-free interest rate | % | |||
| Volatility | % | |||
| Dividend yield | % | |||
| (1) | |
| (2) |
| 20 |
NOTE 11 - INCOME TAXES
The
Company calculates its income tax expense during interim periods based upon applying an estimated annual effective income tax rate to
its year-to-date income, considering, any significant, unusual or infrequently occurring items which have been recorded for the interim
period. The provision for income taxes for the three and nine months ended September 30, 2026, and 2025 differs from the amount that
would be provided by applying the statutory U.S. federal income tax rate of
For the periods ended three and nine months ended September 30, 2026, and 2025, a full income tax valuation allowance was in effect, which resulted in the Company having no income tax expense for these periods. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated in the future to allow the Company to use its existing deferred tax assets. Currently, significant objective negative evidence was evaluated by the Company’ management including the existing net operating loss carryforward composed of the cumulative loss incurred since the Company’s inception, and such objective evidence limits management’s ability to consider other subjective evidence such as the Company’s projections for future growth. Based on this evaluation, a full income tax valuation allowance has been recorded at September 30, 2026 and December 31, 2025, and therefore no deferred income tax asset was recorded since it is not likely to be realized.
The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgement including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known or as the tax environment changes.
NOTE 12 - COMMITMENTS AND CONTINGENCIES
On March 13, 2026, the Company entered into a confidential joint settlement and release agreement (the “Settlement Agreement”) with Ortho-Tain for the full release, waiver and dismissal of all claims asserted by the parties against each other in the lawsuit the Company filed in federal district court in Colorado, Case No. 20 cv 1634 and the lawsuit Ortho-Tain, Inc. filed in the United States District Court for the Northern District of Illinois on July 22, 2020.
In June of 2020, the Company filed a lawsuit in federal district court in Colorado, Case No. 20 cv 1634. The Company’s Complaint alleged that the Company had suffered economic injuries, including lost profits/sales and an injury to its business reputation, as a result of allegedly false, misleading, and defamatory statements made by Ortho-Tain, Inc.’s CEO and legal counsel. In July of 2020, Ortho-Tain, Inc. filed a lawsuit in federal district court in Illinois, Case No. 20 cv 4301. Ortho-Tain’s Complaint alleged that it had suffered economic injuries, including lost profits/sales and an injury to its business reputation, as a result of allegedly unlawful marketing conduct by agents of Vivos.
The Settlement Agreement resolves any claim for relief that was, or could have been alleged, in the foregoing litigation matters. Pursuant to the Settlement Agreement, the Company agreed to pay Ortho-Tain a confidential sum and, among other considerations, not make use of the phrase “Guide” or “Guides” in the formal product name of any of the Company’s oral appliance products and cease direct solicitation and training of independent dental professionals in the use of any Vivos pre-formed tooth positioner products that are competitive with Ortho-Tain. The settlement was paid late March 2026.
There were no new other material commitments or contingencies entered into as of the nine months ended September 30, 2026.
| 21 |
NOTE 13 – RELATED PARTY TRANSACTIONS
The Company has certain office space leases whereby the entity leasing the office space as the lessor is controlled or owned by Dr. Prabhu Rachakonda, the founder of SCN and an employee of the Company. The details of these leases are as follows:
Lease
#1 – In November 2024, SCN entered into an amended office lease agreement for $
Lease
#2 – In January 2024, SCN entered into an office lease agreement when the previous agreement expired. The monthly amount for the
lease is $
Lease
#3 – As of December 31, 2025, the Company has an office lease with
On
June 30, 2026, the Company’s Chairman and Chief Executive Officer, R. Kirk Huntsman purchased $
On July 31, 2026, the Company
entered into a Master Services Agreement (the “MSA”) with The CFO Portal, LLC (“CFO Portal”), under which CFO
Portal provides managed chief financial officer and finance-and-accounting leadership services to the Company, including the services
of Roman Franklin as the Company’s Chief Financial Officer and principal financial officer. Mr. Franklin has been Chief Executive
Officer of CFO Portal since September 2025. Under the MSA, the Company pays CFO Portal a fixed monthly retainer of $
NOTE 14 - NET LOSS PER SHARE OF COMMON STOCK
Basic and diluted net loss per share of Common Stock (“EPS”) is computed by dividing (i) net loss (the “Numerator”), by (ii) the weighted average number of shares of Common Stock outstanding during the period (the “Denominator”).
The calculation of diluted EPS is also required to include the dilutive effect, if any, of stock options, unvested restricted stock awards, convertible debt and Preferred Stock, and other Common Stock equivalents such as pre-funded warrants computed using the treasury stock method, in order to compute the weighted average number of shares outstanding. As of September 30, 2026 and 2025, all Common Stock equivalents were antidilutive.
Presented below are the calculations of the Numerators and the Denominators for basic and diluted EPS (dollars in thousands, except per share amounts):
SCHEDULE OF CALCULATIONS OF NUMERATORS AND DENOMINATORS FOR BASIC AND DILUTED EPS
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| For the Three Months Ended September 30, | For The Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Calculation of Numerator: | ||||||||||||||||
| Net loss | $ | ( | ) | ( | ) | $ | ( | ) | ( | ) | ||||||
| Loss applicable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Calculation of Denominator: | ||||||||||||||||
| Weighted average number of shares of Common Stock outstanding | ||||||||||||||||
| Net loss per share of Common Stock (basic and diluted) | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| 22 |
As of September 30, 2026 and 2025, the following potential Common Stock equivalents were excluded from the computation of diluted net loss per share of Common Stock since the impact of inclusion was antidilutive (in thousands):
SCHEDULE OF COMMON STOCK EQUIVALENTS EXCLUDED FROM COMPUTATION OF DILUTED NET LOSS
| September 30, 2026 | September 30, 2025 | |||||||
| Common stock warrants | ||||||||
| Restricted stock units | - | |||||||
| Common stock options | ||||||||
| Total | ||||||||
NOTE 15 - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS
Fair Value Measurements
Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the measurement of fair value:
Level 1 - Quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date
Level 2 - Other than quoted prices included in Level 1 that are observable for the asset and liability, either directly or indirectly through market collaboration, for substantially the full term of the asset or liability
Level 3 - Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any market activity for the asset or liability at measurement date
As of September 30, 2026 and 2025, the fair value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, and other accrued liabilities approximated their carrying values due to the short-term nature of these instruments.
Recurring Fair Value Measurements
For the three months ended September 30, 2026 and 2025, only the contingent consideration liability discussed in Note 7 was identified as Level 1, Level 2 or Level 3. Level 3 techniques were used in the non-recurring measurement of assets and liabilities acquired in the SCN acquisition.
The Company’s policy is to recognize asset or liability transfers among Level 1, Level 2 and Level 3 as of the actual date of the events or change in circumstances that caused the transfer. During the three months ended September 30, 2026 and 2025 the Company had no transfers of assets or liabilities between levels of the fair value hierarchy.
| 23 |
Significant Concentrations
Credit Risk
The
Company maintains its cash and cash equivalents primarily in depository and money market accounts within three large financial institutions
in the United States. Cash balances deposited at these major financial banking institutions exceed the insured limits. The Company has
not experienced any losses on its bank deposits and believe these deposits do not expose the Company to any significant credit risk.
If the Company was unable to access cash and cash equivalents as needed, the financial position and ability to operate the business could
be adversely affected. As of September 30, 2026, the Company had cash and cash equivalents with five financial institutions in the United
States with an aggregate balance of $
Generally,
credit risk with respect to accounts receivable is diversified due to the number of entities comprising the Company’s customer
base and their dispersion across different geographies and industries. The Company performs ongoing credit evaluations on certain customers
and generally do not require collateral on accounts receivable. No single customer represented more than
Supplier Concentration
As
previously disclosed, the Company relies on third-party suppliers and contract manufacturers for the raw materials and components used
in the Company’s appliances and to manufacture and assemble the Company’s products. As of September 30, 2026, the Company
had five suppliers that accounted for approximately
NOTE 16 – SEGMENT INFORMATION
The
Company operates its business as
The Company’s CODM uses consolidated revenue, gross profit, gross margin and operating loss as the measure of profit or loss. The Company’s CODM assesses performance for the segment and allocates resources and monitors budget versus actual results using consolidated revenue, gross profit, gross margin and operating loss, as disclosed in the statement of operations. The monitoring of budget versus actual results are used in establishing management’s compensation. The measure of segment assets is reported on the balance sheet as total consolidated assets. Revenue and long-lived tangible assets are all located in the U.S.
NOTE 17 – Variable Interest Entities
VARIABLE INTEREST ENTITIES
Variable Interest Entities
The Company evaluates its involvement with variable interest entities (“VIEs”) to determine whether it is required to consolidate such entities and to provide related disclosures.
Consolidated Variable Interest Entity
AIM Detroit, LLC (“AIM Detroit”) is a limited liability company formed to provide management and administrative services to affiliated clinical practices. The Company holds an 80% ownership interest in AIM Detroit.
The Company has determined that AIM Detroit is a variable interest entity because, by design, AIM Detroit’s equity at risk is not sufficient to permit it to finance its activities without additional subordinated financial support. Such support includes, among other things, as-needed member funding during the start-up period and credit support arrangements related to equipment financing.
The Company is the primary beneficiary of AIM Detroit because the Company has substantive decision-making authority over the activities that most significantly affect AIM Detroit’s economic performance and have the obligation to absorb losses or the right to receive benefits that could potentially be significant. Accordingly, AIM Detroit is consolidated in the Vivos’ consolidated financial statements.
| 24 |
SCHEDULE OF VARIABLE INTEREST ENTITY
| September 30, 2026 | December 31, 2025 | |||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Accounts receivable, net of allowance | ||||||||
| Total current assets | ||||||||
| Long-term assets | ||||||||
| Property and equipment, net | ||||||||
| Operating lease right-of-use asset | ||||||||
| Deposits and other | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY/(DEFICIT) | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued expenses | ||||||||
| Current portion of operating lease liability | ||||||||
| Current portion of debt | ||||||||
| Other current liabilities | ||||||||
| Total current liabilities | ||||||||
| Long-term liabilities | ||||||||
| Operating lease liability, net of current portion | ||||||||
| Debt, net of current portion | ||||||||
| Total liabilities | $ | $ | ||||||
NOTE 18 – SUBSEQUENT EVENTS
As
previously disclosed, in April 2026 Vivos Therapeutics, Inc. (the “Company”) received a deficiency notice from the Listing
Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company did not
comply with the continued listing requirements of Nasdaq Listing Rules 5550(b)(1), 5550(b)(2), or 5550(b)(3), which require a listed
company to maintain a minimum of $
On October 20, 2026, the Company received a letter from the Staff stating that, based on the Company’s Current Report on Form 8-K filed October 19, 2026, the Staff has determined that the Company complies with the minimum stockholders’ equity requirement of Nasdaq Listing Rule 5550(b)(1). The letter further stated that if the Company fails to evidence compliance upon the filing of its next periodic report, the Company may be subject to delisting, in which case the Staff would provide written notification to the Company, which may then appeal the Staff’s determination to a Nasdaq Hearings Panel.
On
October 14, 2026 the Company entered into a Mutual Stock Purchase and Asset Exchange Agreement (the “Agreement”) with SOD
Sciences, Inc., a Nevada corporation (“SOD”), providing for the Company’s acquisition of a minority equity interest
in SOD and an undivided fifty percent (50%) co-ownership interest in SOD’s pseudohypoxia early-warning test and related intellectual
property, in exchange for the issuance to SOD of
On October 15, 2026, the Company and SOD entered into a First Amendment to the Agreement (the “First Amendment”), which extended the outside date under the Agreement from October 15, 2026 to October 16, 2026 and established October 16, 2026 as the closing date. On October 16, 2026, the Company and SOD entered into Amendment No. 2 to the Agreement (“Second Amendment”), which corrected a scrivener’s error in the Agreement and the related transaction documents that had described SOD as a Florida corporation. Neither the First Amendment nor the Second Amendment otherwise modified the Agreement.
On October 16, 2026 (the “Closing Date”), at the closing under the Agreement (the “Closing”), the Company and SOD entered into an Assignment and Co-Ownership Agreement (the “Assignment Agreement”), pursuant to which SOD assigned to the Company an undivided fifty percent (50%) co-ownership interest in the pseudohypoxia early-warning test (the “Test Interest”) and related intellectual property (the “Test IP”), free and clear of liens. The Company and SOD hold the Test IP as tenants in common, share equally all revenue and consideration derived from its exploitation and the costs of patent prosecution, maintenance and enforcement, and have mutual consent rights over licenses and settlements. The Assignment Agreement contains customary representations and warranties of SOD regarding title, authority, the absence of liens and conflicting licenses, inventor assignments and non-infringement, which survive for twelve (12) months after the Closing (and, as to title, liens and the completeness of the scheduled patent rights, until sixty (60) days after expiration of the applicable statute of limitations), and provides for a right of first refusal in favor of the Company on any transfer of SOD’s retained interest and a buy-sell exit mechanism at independently appraised fair market value.
On
the Closing Date, the Company completed the acquisition of (i)
Each share of the Series C Preferred
is convertible at the option of the holder into the number of shares of common stock determined by dividing the $
The Company has called
its 2026 annual meeting of stockholders for December 2, 2026 (record date October 9, 2026). In addition to the election of directors and
other customary matters, stockholders are being asked to approve: (i) an amendment to the Company’s Certificate of Incorporation
to effect a reverse stock split of the common stock at a ratio in the range of 1-for-20 to 1-for-40, with the exact ratio and timing to
be determined by the Board of Directors, which may abandon the amendment; (ii) for purposes of Nasdaq Listing Rules 5635(b) and 5635(d),
the issuance of up to
| 25 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the Company’s financial statements and the related notes to those statements included elsewhere in this Quarterly Report on Form 10-Q. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation. The Company’s actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors. See “Cautionary Note Regarding Forward-Looking Statements.” See also Part II, Item A, “Risk Factors.”
Overview
The Company is a revenue stage medical technology and healthcare services company focused on the development and commercialization of innovative treatment alternatives for patients with dentofacial abnormalities and/or patients diagnosed with mild to severe obstructive sleep apnea (“OSA”) and snoring in adults. The Company believes its technologies and conventions represent a significant improvement in the treatment of mild to severe OSA versus other treatments such as CPAP or palliative oral appliance therapies. The Company’s alternative treatments are part of The Vivos Method.
The Vivos Method is an advanced therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by the Company and prescribed by specially trained dentists in cooperation with their medical colleagues. Published studies have shown that using the Company’s customized appliances and clinical treatments led to significantly lower Apnea Hypopnea Index scores and have improved other conditions associated with OSA. Nearly 75,000 patients have been treated to date.
In June 2025, the Company acquired all assets, including operating assets such as sleep testing, diagnostics, and treatment centers of SCN. The Acquisition marked a milestone in the pivot to the Company’s medical provider-focused sales, marketing and distribution model for the Company’s innovative OSA appliances. Under the new model, SCN will provide sleep disorder patients with the opportunity to be candidates for the Company’s advanced, proprietary and FDA-cleared CARE oral medical devices, oral appliances and additional adjunctive therapies and methods. Under customary agreements designed to comply with applicable corporate practice of medicine law, the Company’s operation of SCN allows the Company to manage and capture both diagnostic and diagnostic consulting revenues, representing new higher margin revenue streams for the Company, as well as potential Vivos appliance and related product and service revenue.
See Note 1 to the accompanying financial statements for additional background information on the Company and current product and service offerings.
Third Quarter 2026 Highlights
| ● | Operating loss improved by $0.8 million, or 18%, to $3.9 million, compared to $4.7 million for the third quarter of 2025. | |
| ● | Net loss improved by $3.4 million, or 64%, to $2.0 million, compared to $5.4 million for the third quarter of 2025 due to an increase in Other Income related to Employee Retention Credits. | |
| ● | General and administrative expenses decreased by $1.4 million, or 18%, to $6.5 million, reflecting the Company’s cost reduction initiatives. | |
| ● | Sales and marketing expenses decreased by $0.2 million, or 48%, to $0.2 million. | |
| ● | Total revenue was $6.4 million, a decrease of 5% from the prior-year quarter which was the first full quarter after the acquisition of SCN, as lower product revenue offset a 1% increase in service revenue to $4.6 million. Gross margin was 52%, compared to 58% for the third quarter of 2025. |
| 26 |
Nine Months Ended September 30, 2026
| ● | Total revenue increased by $3.1 million, or 23%, to $16.7 million, driven by a $4.4 million, or 57%, increase in service revenue. | |
| ● | Gross profit increased by $1.8 million, or 23%, to $9.3 million, and gross margin improved to 56% from 55%. |
Recent Developments
Nasdaq Stockholders’ Equity Compliance. On October 20, 2026, the Company received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC confirming that, based on the Company’s Current Report on Form 8-K filed October 19, 2026, the Company complies with the minimum stockholders’ equity requirement of Nasdaq Listing Rule 5550(b)(1). Nasdaq will continue to monitor the Company’s ongoing compliance and, if the Company fails to evidence compliance upon the filing of its next periodic report, the Company may be subject to delisting.
Strategic Transaction with SOD Sciences, Inc. On October 16, 2026, the Company acquired 3,057,879 shares of common stock of SOD Sciences, Inc. (“SOD”), representing at least 11% of SOD’s fully diluted capital stock, and an undivided 50% co-ownership interest in SOD’s pseudohypoxia early-warning test and related intellectual property, in exchange for 12,000 shares of the Company’s Series C Convertible Preferred Stock with an aggregate stated value of $12.0 million. No cash consideration was paid by either party. The Company and SOD share equally in all revenue derived from the test and related intellectual property and in the related patent costs. Under the Agreement, the Company and SOD are to negotiate a joint marketing agreement under which SOD would market the Company’s testing and device products through the American Health Associates and Cleveland Clinic Weston channels, with the Company retaining 80% of the contribution margin on sales of its products through those channels, and a separate agreement addressing the marketing of SOD’s ReBalU Protocol to U.S. sleep-testing centers. The Company is entitled to 50% of the contribution margin on all sales of the test through any channel. If the joint marketing agreement is not signed within 90 days after the closing, either party may submit the unresolved terms to binding determination by an independent expert. There can be no assurance that definitive agreements with American Health Associates or Cleveland Clinic Weston will be signed or that any commercial activity will result. The Company is evaluating the accounting for this transaction, including the fair value of the assets acquired and the classification of the Series C Convertible Preferred Stock. The transaction is not reflected in the accompanying financial statements as of September 30, 2026. See Note 18 to the accompanying financial statements.
Reduction of Senior Secured Debt. In August 2026, the Company completed a qualifying equity financing in excess of the $2.6 million threshold under its Exchange Agreement with Streeterville Capital, LLC, which triggered the exchange of approximately $3.25 million of senior secured debt for 1,812,031 shares of common stock and 2,500 shares of Series B Non-Convertible Preferred Stock. The exchange was completed on August 4, 2026. In addition, on September 2, 2026, the Company exchanged $2,861,270 of principal of the Streeterville note for up to 11,445,080 shares of common stock at an average exchange price of approximately $0.25 per share. These exchanges reduced the Company’s outstanding senior secured indebtedness. As of September 2, 2026, after these exchanges, the outstanding principal balance of the Streeterville note was approximately $3.7 million, as reported in the Company’s Current Report on Form 8-K/A filed September 8, 2026. The Series B Non-Convertible Preferred Stock carries a 9% annual dividend and certain covenants in favor of Streeterville, including consent rights over future financings exceeding $2.5 million in the aggregate.
CFO Transition. Effective July 31, 2026, Bradford Amman voluntarily resigned as Chief Financial Officer and Secretary of the Company. Mr. Amman’s resignation was not the result of any disagreement with the Company on any matter relating to its operations, accounting policies or practices, financial reporting, internal controls, or disclosures. Concurrently, the Board of Directors appointed Roman Franklin as Chief Financial Officer and principal financial officer pursuant to a managed services agreement with The CFO Portal, LLC, a related-party arrangement. Mr. Amman agreed to remain with the Company as a non-executive transition employee for 90 days after July 31, 2026, serving as principal accounting officer, receiving his base salary and benefits and being paid previously deferred compensation during that period, and then to serve as an independent contractor advisor for an additional 180 days at a monthly fee of $13,333, under a Separation, Resignation and Executive Transition Agreement dated July 31, 2026. The Company also agreed to pay his COBRA premiums for up to six months and, subject to approval by the Board of Directors and the effectiveness of a release, to grant him a fully vested award of 250,000 shares of common stock and an option to purchase 150,000 shares of common stock that vests monthly during the advisory period. Any amounts still payable under the agreement will become due, and the option will vest in full, if the Company completes an equity financing of $5 million or more. These payments and benefits are provided in place of severance under his employment agreement.
Material Items, Trends and Risks Impacting the Company’s Business
The Company believes that the following items and trends may be useful in better understanding the Company’s results of operations.
VIP Enrollments (Service Revenue). Enrolling dental practices as VIPs has historically been the first step in the Company’s ability to generate new revenue. As part of the Company’s strategic pivot previously described herein, the Company has phased out the VIP program and no longer offers it to independent dentists.
In addition to enrollment service revenue, the Company offers additional services, such as the Company’s Billing Intelligence Services offering, and MyoSync (formerly MyoCorrect) orofacial myofunctional therapy services, which was introduced in April 2021. Revenue for these services is recognized as the Company’s performance obligations are satisfied in accordance with ASC 606.
| 27 |
Because of the Company’s 2024 marketing and distribution business model pivot, which was accelerated by the Company’s June 2025 acquisition of SCN, the Company has become primarily focused on engaging in strategic collaborations or acquisitions to market the benefits of the Vivos treatment modalities to dentists and other medical providers, including the Company’s cooperative relationships with various medical providers to deliver diagnostic and medical consultation services to people across North America who suffer from OSA. As such, while the Company will continue to recognize minimal VIP enrollment revenue through 2026, the Company believes such revenue will become immaterial. Going forward, the Company no longer expects to recognize revenue on VIP enrollment as the Company’s performance obligations are believed to have been satisfied in accordance with ASC 606.
Product Sales Revenue. Vivos treatment “case starts” are paramount to the Company’s business, as case starts lead to appliance orders and related revenue. Once a provider is fully trained, the Company encourages them to start cases. However, the Company’s historic experience had been that VIPs typically start slowly as they introduce The Vivos Method into their practices. The slow acceptance rate of Vivos appliances with providers led the Company to consider other business models, most notably the medical provider-focused alliance marketing and distribution model announced in 2024 and the 2025 acquisition of SCN, to provide services and sell appliance product. In the Company’s new model, the Company’s biggest challenge to date has been hiring, equipping and training personnel at SCN locations in the Vivos Method, as well as insurance reimbursement. Navigating these challenges has led to increases in service revenue (including sleep testing) and the Company’s goal is to increase case starts and appliance sales as well. Since the Company’s SCN acquisition, the Company has been unable to generate sufficient revenues to pay for all of the Company’s expenses, including debt service, so the Company’s primary business goal is to increase revenues through SCN and also consider other acquisitions or alliances as a means of increasing revenue from services and appliance sales.
In addition, an important aspect of the Company’s strategy to increase product revenues relates to the products and related intellectual property the Company acquired in March 2023 from Advanced Facialdontics, LLC (“AFD”), including a custom single arch device with an FDA 510(k) clearance for treating TMD and/or Bruxism (teeth grinding or clenching). The Company has rebranded the AFD products as Vivos Versa, Vivos Vida and Vivos Vida Sleep.
Clinical Trial Work. The Company’s efforts to engage in research to demonstrate the clinical efficacy of the Company’s products and obtain additional regulatory clearances for the use of the Company’s products is an important aspect of the Company’s overall strategy. In this regard, on May 29, 2023, the Company and Stanford University executed an agreement to commence a sponsored clinical research study to evaluate the efficacy of the Company’s FDA-cleared DNA appliance compared to the standard of care, CPAP for treatment of sleep apnea. The Company’s DNA device is currently indicated for the treatment of mild to severe sleep apnea and jaw repositioning in adults (and in the case of severe OSA, along with positive airway pressure and/or myofunctional therapy, as needed) and has an FDA clearance intended to reduce nighttime snoring and to treat moderate and severe obstructive sleep apnea in children, 6 - 17 years of age who are diagnosed with snoring and/or moderate or severe obstructive sleep apnea and need orthodontic treatment. Enrollment of 150 patients with moderate to severe sleep apnea (apnea-hypopnea index score of 15 or greater) will be randomly assigned to either treatment with the Company’s FDA-cleared DNA appliance or CPAP. The protocol has been finalized, and enrollment began in 2024. In late 2024, the Company’s clinical study conducted in collaboration with Stanford University and evaluating the DNA and CPAP for the treatment of OSA, was placed on hold by Stanford University. The decision to pause the study was made due to low recruitment into the study. The study remained on hold as of the date of this Report.
The Company is working with Stanford University to address the concerns that led to the hold and has continued to engage in discussions with the university. While the Company believes these efforts will facilitate the resumption of the study, there can be no assurance that the hold will be lifted in a timely manner, or at all. Any delay or failure to resolve the issues could impact the development timeline and future prospects for the study. The Company remains committed to the highest standards of patient safety, scientific integrity, and regulatory compliance and will provide updates as material developments occur. This trial may not meet its designated endpoints, and therefore additional FDA clearances for the DNA device may not be obtained.
| 28 |
Inflation. The U.S. has been experiencing a period of inflation which has increased (and may continue to increase) the Company’s and its suppliers’ costs as well as the end cost of the Company’s products to consumers. To date, the Company has been able to manage inflation risk without a material adverse impact on the Company’s business or results of operations. However, inflationary pressures (including increases in the price of raw material components of the Company’s appliances) made it necessary for the Company to adjust the Company’s standard pricing for the Company’s appliance products in 2022 and will be revisited in 2027. The full impact of such price adjustments on sales or demand for the Company’s products is not fully known at this time and may require the Company to adjust other aspects of the Company’s business as the Company seeks to grow revenue and, ultimately, achieve profitability and positive cash flow from operations.
Supply Chain. From time to time, the Company may experience supply chain challenges due to forces beyond the Company’s control. For example, the Suez Canal blockage in 2021 caused some delay in shipments of SleepImage® rings from China. Changes in U.S. or foreign trade policy, including the imposition of new tariffs, increases in existing tariffs or changes in customs classifications, could increase the Company’s costs. Overall, however, as the Company’s appliances are made in the U.S., the Company has not experienced significant supply chain issues as a result of COVID-19 or otherwise, although this may change in future periods.
Middle East Hostilities. In addition, geopolitical instability in the Middle East continues to create uncertainty in global economic conditions and commercial activity. Hostilities in the region, including the attacks by Hamas on Israel in October 2023, Israel’s subsequent military responses, and more recent U.S. and Israeli military actions involving Iran, have contributed to heightened regional and global tensions. These developments, combined with the ongoing effects of Russia’s invasion of Ukraine that began in February 2022, have intensified supply chain constraints, increased commodity price volatility and disrupted international trade flows. If an economic recession or depression commences and is sustained, it could have a material adverse effect on the Company’s business as demand for the Company’s products could decrease. Capital markets uncertainty, with public stock price decreases and volatility, could make it more difficult for the Company to raise capital when needed.
Nasdaq Listing Requirements. The Company is subject to the continued listing requirements of The Nasdaq Stock Market LLC (“Nasdaq”), including the minimum stockholders’ equity requirement (the “Equity Requirement”). During 2026, the Company received notices from Nasdaq regarding its compliance with the Equity Requirement and the $1.00 minimum bid price requirement, as described below. On October 20, 2026, Nasdaq confirmed that the Company complies with the Equity Requirement, subject to ongoing monitoring. The Company intends to hold an annual stockholder’s meeting on December 2, 2026. At this meeting shareholders will vote on a proposed reverse split at a ratio that management believes will resolve Nasdaq’s $1.00 minimum bid price requirement (the “Minimum Bid Requirement”).
The Company has a history of challenges of maintaining compliance with the Nasdaq’s continuing listing requirements. The Company has been subject to multiple Nasdaq listing deficiencies relating to the Minimum Bid Requirement and the Equity Requirement. Nasdaq confirmed on October 20, 2026 that the Company complies with the Equity Requirement. The Company has not regained compliance with the Minimum Bid Requirement as of the date of this Report.
On September 21, 2023, the Company received a written notice from the Nasdaq staff confirming that since, as of that date, the Company failed to meet the Minimum Bid Requirement, and because as of the period ended June 30, 2023 the Company also failed the Equity Requirement, Nasdaq would commence delisting proceedings against the Company. As permitted under Nasdaq rules, the Company appealed the Nasdaq staff’s determination and requested a hearing (the “Hearing”) before a Nasdaq Hearing Panel (the “Hearing Panel”). The Hearing request stayed any delisting or suspension action by the Nasdaq staff pending the issuance of the Hearing’s Panel decision. The Hearing took place on November 9, 2023.
Prior to the date of the Hearing, the Company effectuated a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-25 (the “Reverse Stock Split”). The Reverse Stock Split became effective on October 25, 2023, and the Company’s common stock began trading on a post-Reverse Stock Split basis on the Nasdaq on October 27, 2023. To satisfy the Minimum Bid Requirement, the Company’s common stock was required to trade at above $1.00 per share for at least 10 trading days, and this was achieved on November 9, 2023. The Company therefore regained compliance with the Minimum Bid Requirement in November 2023.
| 29 |
At the Hearing on November 9, 2023, the Company presented its plan to regain compliance with the Equity Requirement, which included raising additional equity capital. On November 30, 2023, the Company received a letter from the Hearings Panel that, subject to certain conditions, the Hearings Panel granted the Company’s request to continue to be listed on Nasdaq. On February 23, 2024 the Company presented its plan of compliance to the Hearings Committee. On May 6, 2024, the Company received written notice from the Nasdaq staff indicating that the Company had regained compliance with the Equity Requirement.
On May 16, 2024, the Company received a further written notice from Nasdaq indicating that, as of March 31, 2024, the Company failed to comply with the Equity Requirement. On June 25, 2024, the Company reported in a Current Report on Form 8-K that the Company believed the Company had stockholders’ equity of at least $2.5 million as of the date of the filing of such report as a result of the Company’s closing of a $7.5 million equity private placement on June 10, 2024.
On June 27, 2024, the Company met with the Panel to discuss the Company’s past, current, and anticipated future compliance with the Equity Requirement, and requested the continued listing of its securities on Nasdaq.
On July 5, 2024, the Company was notified that the Panel granted the Company’s request for continued listing on Nasdaq, subject to the Company’s filing of the Form 10-Q for the quarter ended June 30, 2024, with the Securities and Exchange Commission, evidencing the Company’s compliance with the Equity Requirement. The Company made such filing in a timely manner.
On April 17, 2026, the Company received a letter (“Letter”) from the Listing Qualifications Staff (the “Staff”) of Nasdaq indicating that the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the year ended December 31, 2025 (the “Form 10-K”), did not satisfy the continued listing requirement under the Equity Requirement. As reported in its Form 10-K, as of December 31, 2025 the Company had a negative stockholders’ equity of approximately $1.55 million. The Staff’s notice has no immediate impact on the listing of the Company’s common stock on Nasdaq.
On June 5, 2026, the Company received a notice from the Listing Qualifications Staff of Nasdaq indicating that, based on the closing bid price of the Company’s common stock from April 23, 2026 through June 4, 2026, the Company was no longer in compliance with the Minimum Bid Requirement. The Company has a compliance period of 180 calendar days, through December 2, 2026, to regain compliance, and as of the date of this report it has not regained compliance. The Company is seeking stockholder approval at its December 2, 2026 annual meeting of a reverse stock split of the common stock at a ratio in the range of 1-for-20 to 1-for-40, to be determined by the Board of Directors, to raise the bid price and regain compliance. If the Company does not regain compliance by December 2, 2026, it may be eligible for a second 180-day compliance period if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, other than the minimum bid price requirement, and notifies Nasdaq of its intent to cure the deficiency. There can be no assurance that the Company will regain compliance or that Nasdaq will grant a second compliance period.
The Company has taken affirmative steps since December 31, 2025 to remedy the Minimum Stockholders’ Equity Requirement. Specifically, as previously reported, the Company engaged in two equity financing transactions during the first quarter ended March 31, 2026 for aggregate gross proceeds of $6.8 million: a $4.6 million warrant exercise inducement transaction and $2.25 million private placement with an existing investor. The Company also engaged in an approximately $2.1 million private placement in the second quarter ended June 30, 2026 with one new and one existing investor. During the third quarter ended September 30, 2026, the Company exchanged $3,250,000 of principal of its senior secured note held by Streeterville Capital, LLC for 1,812,031 shares of common stock and 2,500 shares of Series B Non-Convertible Preferred Stock on August 4, 2026, and exchanged a further $2,861,270 of principal for up to 11,445,080 shares of common stock on September 2, 2026. The Company also sold shares of common stock under its at-the-market offering program in the third quarter, with net proceeds of approximately $1.9 million. These transactions improved stockholders’ equity but did not by themselves restore compliance, as the Company’s total stockholders’ equity at September 30, 2026 was approximately $2.4 million ($2.2 million including non-controlling interest), below the $2.5 million minimum. On October 16, 2026, the Company issued 12,000 shares of Series C Convertible Preferred Stock, with an aggregate stated value of $12.0 million, to SOD in exchange for 3,057,879 shares of SOD common stock and an undivided 50% co-ownership interest in SOD’s pseudohypoxia early-warning test and related intellectual property, as described under “Recent Developments” above. In its Current Report on Form 8-K filed October 19, 2026, the Company reported unaudited pro forma stockholders’ equity of approximately $6.6 million as of June 30, 2026, giving effect to the closing, and stated that it expects the closing to increase its stockholders’ equity by more than $10 million, subject to completion of the purchase price allocation and review by its independent registered public accounting firm. On October 20, 2026, Nasdaq notified the Company that it had regained compliance with the Minimum Stockholders’ Equity Requirement, subject to Nasdaq’s continued monitoring.
In accordance with the Nasdaq Listing Rules, the Company timely submitted a plan to regain compliance with the Stockholders’ Equity Requirement for the Staff’s consideration. Following the Company’s qualifying equity financing in August 2026, the related exchange of senior secured debt for equity, and the October 16, 2026 issuance of Series C Convertible Preferred Stock in the SOD transaction described under “Recent Developments” above, the Company filed a Current Report on Form 8-K on October 19, 2026, and on October 20, 2026, Nasdaq notified the Company that it complies with the Equity Requirement. Nasdaq will continue to monitor the Company’s ongoing compliance and, if the Company fails to evidence compliance upon the filing of its next periodic report, the Company may be subject to delisting.
The Company intends to seek shareholder approval at its annual meeting scheduled for December 2, 2026, to effect a reverse stock split at a ratio management believes will enable the Company to regain compliance with the Minimum Bid Requirement. However, because the shareholder vote is scheduled for the same date as the expiration of the compliance period, the timing of the proposed reverse stock split may not allow the Company sufficient time to regain compliance before the deadline. There can be no assurance that shareholders will approve the proposed reverse stock split, that the Company will be able to implement the reverse stock split in time to regain compliance, or that the Company will otherwise regain compliance with the Minimum Bid Requirement. If the Company fails to regain compliance within the applicable compliance period, its common stock may be subject to delisting from Nasdaq.
| 30 |
The Company anticipates that its new medical provider-focused strategic marketing and distribution alliance model will also positively impact the Company’s revenue growth and stockholders’ equity in upcoming fiscal quarters. However, there is a risk that the Company will be unable to raise sufficient capital, reduce costs sufficiently or generate sufficient revenue or operating results to maintain compliance with the Equity Requirement. If the Company fails to achieve ongoing compliance and its common stock is delisted by Nasdaq, such delisting would likely have a material adverse effect on the Company’s stock price, the ability of the Company’s stockholders to buy or sell their common stock, the Company’s ability to raise capital and on the Company’s reputation, all of which could make it significantly more difficult to operate.
Key Components of Consolidated Statements of Operations
Net revenue. The Company recognizes revenue when the Company satisfies its performance obligations over time as its customers receive the benefit of the promised goods and services, which generally occurs over a short period of time. Performance obligations with respect to appliance sales are typically satisfied at a point in time by shipping or delivering products to the Company’s VIPs or to the sleep clinic, through the Company’s new strategic alliance model. In the case of enrollment or service revenue, upon the Company’s satisfaction of performance obligations associated with VIP enrollments. Revenue consists of the gross sales price, net of estimated allowances, discounts, and personal rebates that are accounted for as a reduction from the gross sale price.
In the case of product purchased by clinics managed by the Company’s subsidiary for inclusion in a treatment protocol, the sales price of the Vivos device is recognized by the Company and becomes a component of cost of sales of the treatment center service provided to the patient. For the treatment centers, the intercompany account is used to fulfil the account payable obligation and recognize the expense of the goods and services in cost of sales.
Cost of sales. Cost of goods sold primarily consists of direct costs attributable to the purchase from third party suppliers and related products. It also includes freight costs, fulfillment, distribution, and warehousing costs related to products sold.
Sales and marketing. Sales and marketing costs primarily consist of personnel costs for employees engaged in sales and marketing activities, commissions, advertising and marketing costs, website enhancements, and conferences for the Company’s sales and marketing staff.
General and administrative expenses. General and administrative (“G&A”) expenses consist primarily of personnel costs for the Company’s administrative, human resources, finance and accounting employees, and executives. General and administrative expenses also include contract labor and consulting costs, travel-related expenses, legal, auditing and other professional fees, rent and facilities costs, repairs and maintenance, and general corporate expenses.
Depreciation and amortization expense. Depreciation and amortization expense is comprised of depreciation expense related to property and equipment, amortization expense related to leasehold improvements, and amortization expense related to identifiable intangible assets.
Other income. Other income relates to the excess warrant fair value and change in fair value of warrant liability and contingent consideration for the purchase of SCN.
| 31 |
Results of Operations
Comparison of the three and nine months ended September 30, 2026 and 2025
The Company’s consolidated statements of operations for the three and nine months ended September 30, 2026 and 2025 (which includes incremental revenue recognized from the operations of SCN since June 10, 2025) are presented below (dollars in thousands):
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||
| 2026 | 2025 | Change | 2026 | 2025 | Change | |||||||||||||||||||
| Revenue | ||||||||||||||||||||||||
| Product revenue | $ | 1,772 | $ | 2,195 | $ | (423 | ) | $ | 4,567 | $ | 5,893 | $ | (1,326 | ) | ||||||||||
| Service revenue | 4,642 | 4,588 | 54 | 12,141 | 7,726 | 4,415 | ||||||||||||||||||
| Total revenue | 6,414 | 6,783 | (369 | ) | 16,708 | 13,619 | 3,089 | |||||||||||||||||
| Cost of sales (exclusive of depreciation and amortization shown separately below) | 3,100 | 2,846 | 254 | 7,382 | 6,065 | 1,317 | ||||||||||||||||||
| Gross profit | 3,314 | 3,937 | (623 | ) | 9,326 | 7,554 | 1,772 | |||||||||||||||||
| Gross profit % | 52 | % | 58 | % | 56 | % | 55 | % | ||||||||||||||||
| Operating expenses | ||||||||||||||||||||||||
| General and administrative | 6,450 | 7,884 | (1,434 | ) | 22,533 | 19,181 | 3,352 | |||||||||||||||||
| Sales and marketing | 210 | 403 | (193 | ) | 614 | 1,018 | (404 | ) | ||||||||||||||||
| Depreciation and amortization | 550 | 384 | 166 | 1,515 | 867 | 648 | ||||||||||||||||||
| Operating loss | (3,896 | ) | (4,734 | ) | 838 | (15,336 | ) | (13,512 | ) | (1,824 | ) | |||||||||||||
| Non-operating income (expense) | ||||||||||||||||||||||||
| Other expense | (981 | ) | (679 | ) | (302 | ) | (3,199 | ) | (850 | ) | (2,349 | ) | ||||||||||||
| Other income | 2,906 | 13 | 2,893 | 3,290 | 86 | 3,204 | ||||||||||||||||||
| Net loss | $ | (1,971 | ) | $ | (5,400 | ) | $ | 3,429 | $ | (15,245 | ) | $ | (14,276 | ) | $ | (969 | ) | |||||||
Comparison of the three months ended September 30, 2026 and 2025
Revenue
Revenue decreased by approximately $0.4 million, or 5%, to approximately $6.4 million for the three months ended September 30, 2026 compared to $6.8 million for the three months ended September 30, 2025. The decrease in total revenue during the third quarter of 2026 was impacted by a decrease of approximately $0.4 million in product revenue offset by a slight increase in service revenue. The decrease in product revenue is attributable to a decrease in appliance sales to VIPs of approximately $1.1 million related to the Company’s previously stated change in business strategy, offset by a decrease of approximately $0.5 million in discounts offered and an increase in diagnostic reports of $0.1 million. The increase in service revenue is attributable to approximately $1.5 million in sleep testing services primarily generated from SCN and an increase of approximately $0.6 million of revenue generated from Vivos treatment to patients launched at two SCN locations, offset by a decrease of approximately $0.1 million in VIP enrollment revenue and approximately $0.1 million from sponsorship, seminar and other service revenue.
Cost of Sales and Gross Profit
Cost of sales increased $0.3 million or 9% to approximately $3.1 million for the three months ended September 30, 2026, compared to $2.8 million for the three months ended September 30, 2025. This was primarily attributable to higher costs associated with diagnostic services and patient therapy, including the addition of staff at the Vivos treatment centers.
For the three months ended September 30, 2026, gross profit decreased by approximately $0.6 million to $3.3 million. This decrease was attributable to the decrease in revenue of approximately $0.4 million and increase in cost of sales of $0.3 million. Gross margin decreased to 52% for the three months ended September 30, 2026, compared to 58% for the three months ended September 30, 2025 due to the decrease in Product Revenue.
| 32 |
General and Administrative Expenses
General and administrative expenses decreased $1.4 million, or 18%, to approximately $6.5 million for the three months ended September 30, 2026, as compared to $7.9 million for the three months ended September 30, 2025. The decrease was primarily attributable to a $0.8 million reduction in professional fees; a $0.3 million reduction in equipment maintenance; a $0.2 million decrease in office expenses and supplies and a decrease in infrastructure expenses, of $0.1 million. The decrease reflects the Company’s continued focus on cost reduction and the absence of certain integration costs incurred in the prior-year period following the acquisition of SCN.
Sales and Marketing
Sales and marketing expenses decreased $0.2 million, or 48%, to approximately $0.2 million for the three months ended September 30, 2026, as compared to $0.4 million for the three months ended September 30, 2025, which is attributable in significant part to the Company’s focus on reducing costs.
Depreciation and Amortization
Depreciation and amortization expense increased $0.2 million for the three months ended September 30, 2026 due to assets being placed into service.
Other Income/(Expense)
Other (Expense) increased $0.3 million during the three months ended September 30, 2026. The increase is primarily attributable to interest expense from the short-term financing agreements entered into in the third quarter. Other Income was $2,906,000 and $13,000 for the three months ended September 30, 2026 and 2025, respectively. The increase in Other Income is primarily attributable to the reversal of the Company’s previously recorded Employee Retention Credit liability of approximately $2.9 million, because management concluded that repayment of the credits is no longer deemed probable. See Note 7 to the accompanying unaudited condensed consolidated financial statements.
Comparison of the nine months ended September 30, 2026 and 2025
Revenue
Revenue increased by approximately $3.1 million, or 23%, to approximately $16.7 million for the nine months ended September 30, 2026 compared to $13.6 million for the nine months ended September 30, 2025. The increase in total revenue during the period was impacted by an increase of approximately $4.4 million in service revenue offset by a decrease of approximately $1.3 million in product revenue. The $ 1.3 million decrease in product revenue was attributable to a decrease in the sales volume of the Company’s On Demand Orthodontic (ODO) devices to VIP members. During 2026 the Company has shifted its marketing focus to concentrate on providing services to patients who will potentially utilize the Company products, and accordingly the Company experienced a $4.4 million increase for this period in its service revenues due to new patients being treated in its Sleep and Airway facilities in Las Vegas and Henderson, Nevada.
Cost of Sales and Gross Profit
Cost of sales increased $1.3 million or 22% to approximately $7.4 million for the nine months ended September 30, 2026, compared to $6.1 million for the nine months ended September 30, 2025. This was primarily related to higher costs associated with diagnostic services and patient therapy, including the addition of staff at the Vivos treatment centers.
For the nine months ended September 30, 2026, gross profit increased by approximately $1.8 million to $9.3 million compared to approximately $7.6 million for the nine months ended September 30, 2025. This increase was attributable to the increase in revenue of approximately $3.1 million partially offset by the increase in cost of sales of $1.3 million. Gross margin for the nine months ended September 30, 2026 and 2025 was 56% and 55%, respectively.
| 33 |
General and Administrative Expenses
General and administrative expenses increased by approximately $3.4 million, or approximately 17%, to approximately $22.5 million for the nine months ended September 30, 2026, as compared to $19.2 million for the nine months ended September 30, 2025. The primary driver of this increase related to the costs associated with establishing the two Sleep and Airway treatment facilities in Las Vegas and Henderson, Nevada, including an increase in salaries and related compensation of approximately $1.7 million; an increase in professional fees of approximately $ 0.9 million; an increase in occupancy expenses of approximately $ 0.6 million and an increase in other costs of approximately $0.3 million.
Sales and Marketing
Sales and marketing expenses decreased by $0.4 million to $0.6 million for the nine months ended September 30, 2026, compared to $1.0 million for the nine months ended September 30, 2025. This decrease was primarily driven by the Company’s decrease in sales and marketing campaigns, lower commissions paid to the Company’s employees for digital media services and reduction in use of marketing supplies.
Depreciation and Amortization
Depreciation and amortization expense increased $0.6 million to approximately $1.5 million for the nine months ended September 30, 2026 from $0.9 million for the nine months ended September 30, 2025. Depreciation and amortization increased during the period due to assets being placed into service during the period.
Other Income/(Expense)
Other (Expense) increased $2.3 million due primarily to interest expense, including interest expense from the short-term financing agreements entered into in the third quarter, offset by an increase in Other Income of $3.2 million, which includes the reversal of the Company’s previously recorded Employee Retention Credit liability of approximately $2.9 million and $0.3 million related to the valuation change in the contingent earnout related to the acquisition of SCN.
Liquidity and Capital Resources
The financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company has incurred losses since inception, including $1.9 and $5.4 million for the three months ended September 30, 2026 and 2025, respectively, and $15.1 million and $14.3 million for the nine months ended September 30, 2026 and 2025, respectively, resulting in an accumulated deficit of approximately $140.5 million as of September 30, 2026.
Net cash used in operating activities amounted to approximately $12.3 million and $11.5 million for the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, the Company had total liabilities of approximately $20.7 million.
On June 5, 2026, the Company entered into an Exchange Agreement with Streeterville Capital, LLC pursuant to which Streeterville agreed to exchange up to approximately $4.5 million of outstanding senior secured debt for a combination of perpetual non-convertible preferred stock and shares of common stock, contingent upon the Company completing certain qualifying equity financings. On June 18, 2026, the parties entered into a letter agreement extending the outside date for completion of the initial qualifying financing of at least $2.6 million from June 15, 2026 to August 31, 2026. In August 2026, the Company completed a qualifying financing in excess of the $2.6 million threshold, triggering the exchange of approximately $3.25 million of senior secured debt for 1,812,031 shares of common stock and 2,500 shares of Series B Non-Convertible Preferred Stock, which was completed on August 4, 2026. On September 2, 2026, the Company exchanged an additional $2,861,270 of principal of the Streeterville note for 11,445,080 shares of common stock at an average exchange price of approximately $0.25 per share. See Note 9 to the accompanying financial statements for additional information.
On June 30, 2026, the Company closed a private placement with V-Co Investors 4 LLC and Bigger Capital Fund, LP for aggregate proceeds of approximately $2.1 million through the sale of units consisting of Series A Convertible Preferred Stock and warrants at a purchase price of $0.582 per unit. In connection with the transaction, the Company filed a Certificate of Designation creating the Series A Convertible Preferred Stock and entered into a registration rights agreement. A portion of the proceeds reflected the conversion of previously outstanding bridge financing.
| 34 |
During 2026, the Company has taken steps to strengthen its balance sheet and reduce costs, including raising equity capital in each of the first three quarters of 2026, exchanging approximately $6.1 million of senior secured debt for equity, and reducing general and administrative and sales and marketing expenses for the third quarter by a combined $1.6 million compared to the prior-year period. Notwithstanding these actions, the Company continues to face significant liquidity challenges, as described below.
As of September 30, 2026, the Company had approximately $0.2 million in cash and cash equivalents, which will not be sufficient to fund operations and strategic objectives over the next twelve months from the date of the issuance of these financial statements. Without additional financing, these factors raise substantial doubt regarding the Company’s ability to continue as a going concern.
As of September 30, 2026, the Company had approximately $2.3 million of outstanding principal under its senior secured note with Streeterville Capital, LLC, which is due on June 10, 2027. The Company expects to satisfy this obligation through available cash, additional financing, or other sources of liquidity.
The Company has implemented cost savings measures in its legacy business that have reduced cash used in operations. In the latter part of the third quarter of 2026 and through the present date, management has continued to reduce its operating costs and streamline operations. The Company estimates it has eliminated over $5 million in annual operating costs, with further cuts and efficiencies still being worked on. During the first nine months of 2025, many one-time costs related to the acquisition of SCN were recognized and were not recurring in 2026.
In addition to the Company’s material cost reduction initiatives, the Company has also embarked on a number of important clinical initiatives aimed at raising the level of services offered to patients at both SCN and SAMC centers. Such clinical programs are expected to yield significant revenue enhancements at high gross margins. These initiatives include, but are not limited to, EEG testing and treatment for insomnia and other non-OSA forms of sleep disorders, the distribution and set up of PAP and CPAP treatments, and Remote Patient Monitoring (RPM) of CPAP users from both existing CPAP populations as well as new CPAP enrollments from new testing being conducted each month. In addition, payer contracts that have not been renegotiated in some time are actively being renegotiated with payers. The Company has retained professional third-party experts to assist and guide the negotiation process. All told, these collective clinical and payer contract initiatives are expected to contribute materially to the Company’s revenue and overall profit margins in the fourth quarter of 2026 and increasingly throughout 2027.
As such, the Company has funded its operations through equity raises and debt financings during the nine months ended September 30, 2026 and the fiscal year ended December 31, 2025. The Company was required to obtain additional financing to satisfy its cash needs, including funding the SCN acquisition, and increasing the Company’s stockholders’ equity for Nasdaq compliance purposes as the Company seeks to increase revenue with a view towards ultimately achieving positive cash flow operations in 2027. On October 16, 2026, the Company issued 12,000 shares of Series C Convertible Preferred Stock to acquire interests in SOD. The SOD transaction provided no cash to the Company.
Until the Company has attained positive cash flow, the Company’s management is reviewing all options to obtain additional financing to fund the Company’s operations. The Company financed the SCN acquisition from the issuance of senior secured debt and equity securities. The Company expects the SCN acquisition will ultimately allow the Company to achieve positive cash flows; however, there is a risk this may not occur. The Company originally expected the Strategic Alliance Agreement (“SAA”) with Rebis Health entered into in June 2024 to increase patient volume, drive top line revenue and lower customer acquisition costs and overhead. However, due to ongoing delays at Rebis Health that are beyond the Company’s control, the Company is currently re-evaluating and lowering its revenue expectations under the SAA. As such, the Company seeks to acquire other sleep centers in transactions similar to the SCN acquisition or enter into other strategic alliances. There can be no assurances that adequate additional funding will be available on favorable terms, or at all. If such funds are not available in the future, or the SAA or similar alliances or acquisitions do not result in the patient volume, appliance sales and financial results within the timeframes the Company expects, the Company may be required to delay, significantly modify or terminate some or all of the Company’s operations, all of which could have a material adverse effect on the Company and the Company’s stockholders.
The Company does not have any off-balance sheet arrangements, as defined by applicable regulations of the SEC, that are reasonably likely to have a current or future material effect on the Company’s financial condition, results of operations, liquidity, capital expenditures or capital resources.
Cash Flows
The following table presents a summary of the Company’s cash flow for the nine months ended September 30, 2026 and 2025 (in thousands):
| 2026 | 2025 | |||||||
| Net cash (used in) provided by: | ||||||||
| Operating activities | $ | (12,334 | ) | $ | (11,451 | ) | ||
| Investing activities | (495 | ) | (5,945 | ) | ||||
| Financing activities | 11,047 | 14,223 | ||||||
| 35 |
Net cash used in operating activities increased by approximately $0.9 million to $12.3 million for the nine months ended September 30, 2026, compared to $11.5 million for the same period in 2025. The increase was primarily attributable to a higher net loss, partially offset by changes in operating assets and liabilities, including increases in accounts payable and accrued expenses and a decrease in the employee retention credit liability.
For the nine months ended September 30, 2026, net cash used in investing activities consisted of approximately $0.5 million related to the acquisition of property, plant and equipment. This compares to net cash used in investing activities for the nine months ended September 30, 2025 of approximately $5.1 million for payment of a business acquisition and capital expenditures of approximately $0.8 million related to internally developed software.
Net cash provided by financing activities of $11.0 million for the nine months ended September 30, 2026, is attributable to proceeds of approximately $6.2 million from the issuance of common stock, proceeds of approximately $4.2 million from the exercise of warrants, proceeds of approximately $2.2 million from the issuance of debt, proceeds of approximately $3.6 million for the issuance of preferred stock and proceeds of approximately $1.6 million from the issuance of warrants, offset by $6.7 million of debt payments.
Critical Accounting Policies Involving Management Estimates and Assumptions
The Company’s critical accounting policies and estimates are described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The Company has reviewed and determined that those critical accounting policies and estimates remain the Company’s critical accounting policies and estimates as of and for the three and nine months ended September 30, 2026.
Recent Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed in Note 1 to the accompanying condensed consolidated financial statements included in this Report, the Company believes that the impact of recently issued standards that are not yet effective is not expected to have a material impact on the Company’s financial position or results of operations upon adoption. For additional information on recently issued accounting standards and the Company’s plans for adoption of those standards, please refer to the section titled Recent Accounting Pronouncements under Note 1 to the accompanying condensed consolidated financial statements included in this Report.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Not applicable to smaller reporting companies.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
The Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) are designed to ensure that information required to be disclosed by the Company in reports the Company files or submits under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the appropriate time periods, and that such information is accumulated and communicated to the Company’s Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely discussions regarding required disclosure. The Company, under the supervision of and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, have evaluated the effectiveness of the Company’s disclosure controls and procedures. Based on that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer concluded that the design and operation of the Company’s disclosure controls and procedures were effective, at the reasonable assurance level, as of the end of the period covered by this Report.
Changes in Internal Control over Financial Reporting
During the quarter ended September 30, 2026, the Company’s former Chief Financial Officer resigned. In connection with this departure, the Company engaged The CFO Portal, LLC to provide outsourced CFO services, with Roman Franklin serving as the Company’s Chief Financial Officer and principal financial officer. Management evaluated the impact of these changes on the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) and determined that these changes did not materially affect, and are not reasonably likely to materially affect, the Company’s internal control over financial reporting.
| 36 |
PART II – OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Below is a description of the Company’s outstanding pending litigation matters. Litigation is subject to inherent uncertainties and an adverse result in the below described or other matters may arise from time to time that may harm the Company’s business.
Item 1A. Risk Factors
The Company is voluntarily providing in this Item 1A. updated risk factors associated with SCN, the Acquisition, the Company’s October 2026 transaction with SOD Sciences, Inc. and the Series C Convertible Preferred Stock issued in it, the accounting for that transaction, the listing of the Company’s common stock on Nasdaq and the Company’s debt and related matters.
The Company may not realize the anticipated benefits of its October 2026 transaction with SOD Sciences, Inc., and the value of what the Company acquired could decline or be impaired.
On October 16, 2026, the Company acquired 3,057,879 shares of common stock of SOD Sciences, Inc., a privately held Nevada corporation (“SOD”), and an undivided 50% co-ownership interest in SOD’s pseudohypoxia early-warning test and related intellectual property (the “Test IP”), in exchange for 12,000 shares of the Company’s Series C Convertible Preferred Stock (the “SOD Transaction”). The SOD shares represent at least 11% of SOD’s fully diluted capital stock, so the Company is a minority stockholder and does not control SOD. There is no public market for the SOD shares, and the Company may not be able to sell them at a price it considers acceptable, or at all. The value of the SOD shares depends on SOD’s results of operations and financial condition, which the Company does not control.
The Company owns the Test IP jointly with SOD as a tenant in common. Under the Assignment and Co-Ownership Agreement, the Company and SOD share equally all revenue from the test and the costs of patent prosecution, maintenance and enforcement, and each party has consent rights over licenses and settlements. As a result, the Company may be unable to license, enforce or commercialize the Test IP without SOD’s agreement, and the Company will bear half of the costs of patent prosecution, maintenance and enforcement.
The Company’s ability to benefit from the SOD Transaction depends on commercial arrangements that have not been finalized. Following the closing, the Company and SOD are to negotiate a joint marketing agreement, under which SOD would market the Company’s sleep testing and oral appliance products through SOD’s relationships with American Health Associates (“AHA”) and Cleveland Clinic Weston, and a separate agreement for marketing SOD’s ReBalU Protocol to sleep testing centers. As of October 19, 2026, none of these agreements, including the definitive agreements SOD is to seek with AHA and Cleveland Clinic Weston, had been signed. Any arrangement with AHA is also subject to approval by the bankruptcy court in AHA’s pending bankruptcy proceeding. Even if the agreements are signed, they may be on terms less favorable than the Company expects, and the AHA and Cleveland Clinic Weston channels may not produce meaningful revenue.
The pseudohypoxia test is also unproven. It may not achieve clinical validation, regulatory clearance or market acceptance, and the Company’s existing FDA clearances for its oral appliances do not cover the test. Any revenue or contribution margin from the test will depend on clinical validation, regulatory status, testing volume, pricing and the costs allocated under definitive agreements, and may be lower than the Company expects or may never materialize.
Most of SOD’s representations and warranties to the Company survive for only twelve months after the closing, which may limit the Company’s remedies if problems with SOD or the Test IP are discovered later. If the SOD Transaction does not produce the benefits the Company expects, the Company may be required to record a non-cash impairment charge on the SOD shares or the Test IP, which would reduce the Company’s results of operations and stockholders’ equity. The Company also issued Series C Convertible Preferred Stock, which is convertible into a substantial number of shares of common stock, to complete the transaction. See the next risk factor.
| 37 |
The conversion of the Series C Convertible Preferred Stock issued in the SOD Transaction could result in substantial dilution to the Company’s existing stockholders, and sales of the shares issued on conversion could reduce the market price of the common stock.
The 12,000 shares of Series C Convertible Preferred Stock issued to SOD (the “Series C Preferred”) have a stated value of $1,000 per share, or $12.0 million in total, and are convertible at SOD’s option into common stock at a fixed conversion price of $0.15 per share. At that price, the Series C Preferred is convertible into up to 80,000,000 shares of common stock, compared with 33,820,768 shares of common stock outstanding at September 30, 2026, and the Company has issued additional shares since then. Based on the $0.098 closing price of the common stock on November 13, 2026, 80,000,000 shares would have a market value of approximately $7.8 million, compared with the $12.0 million stated value of the Series C Preferred. The conversion price does not reset if the market price of the common stock falls. Issuing those shares would substantially reduce the percentage ownership and voting power of the Company’s existing stockholders.
Until the Company’s stockholders approve the issuance of shares above the exchange cap for purposes of Nasdaq Listing Rule 5635(a), no more than 6,718,517 shares of common stock, which is 19.99% of the shares outstanding before the SOD agreement was signed, may be issued on conversion, and neither the Company nor SOD can waive that cap. The Company has asked its stockholders to approve the issuance of the remaining shares at its annual meeting on December 2, 2026, but there is no assurance that stockholders will approve the proposal. If they do, up to 80,000,000 shares could be issued on conversion, which is approximately 238% of the 33,820,768 shares outstanding on the October 9, 2026 record date. If they do not, the balance of the Series C Preferred will remain outstanding as preferred stock that ranks equally with the Company’s Series A and Series B preferred stock and ahead of the common stock on liquidation.
SOD may not convert to the extent that it and its affiliates would then beneficially own more than 4.99% of the outstanding common stock (a limit that SOD may increase to 9.99% on 61 days’ notice), but SOD could convert and sell shares in stages over time. The Series C Preferred also participates in any dividends declared on the common stock on an as-converted basis and votes with the common stock on an as-converted basis, subject to the limits described above. Sales of a substantial number of shares of common stock issued on conversion, or the perception that those sales could occur, could reduce the market price of the common stock. If the Company effects the reverse stock split described below, the conversion price and the share amounts in the exchange cap will be adjusted proportionally, so that the percentage of the Company’s outstanding common stock issuable on conversion is not changed by the reverse stock split.
The accounting for the SOD Transaction has not been completed, and the final accounting could differ from the Company’s expectations in a way that affects its stockholders’ equity and its compliance with Nasdaq’s stockholders’ equity requirement.
The Company is still evaluating the accounting for the SOD Transaction, including the fair value of the SOD shares and the Test IP and the classification and measurement of the Series C Preferred. The transaction closed after September 30, 2026 and is not reflected in the Company’s condensed consolidated financial statements as of that date, when the Company’s total stockholders’ equity was approximately $2.4 million ($2.2 million including non-controlling interest), which is below the $2.5 million Nasdaq requirement. In its Current Report on Form 8-K filed on October 19, 2026, the Company stated that it expected the transaction to increase its stockholders’ equity by more than $10 million, based on its initial purchase price allocation, which remains subject to adjustment for twelve months after the closing, to completion of the allocation and to review by the Company’s independent registered public accounting firm. In that report, the Company also stated that its unaudited pro forma stockholders’ equity as of June 30, 2026, giving effect to the closing, was approximately $6.6 million. The final accounting could result in a lower value for the assets the Company acquired, or in classifying the Series C Preferred other than as permanent stockholders’ equity, either of which would reduce or eliminate the expected increase. On September 29, 2026, the Company engaged Haynie and Company as its independent registered public accounting firm, replacing Baker Tilly US, LLP. Haynie and Company has not previously audited the Company’s financial statements, and its review of the Company’s financial statements, including the accounting for the SOD Transaction, could lead to changes from the Company’s expectations.
Nasdaq Listing Rule 5550(b)(1) requires the Company to maintain stockholders’ equity of at least $2.5 million (the “Minimum Stockholders’ Equity Requirement”). The Company’s total stockholders’ equity at September 30, 2026 was approximately $2.4 million ($2.2 million including non-controlling interest), which is below $2.5 million. On October 20, 2026, based on the Company’s Current Report on Form 8-K filed October 19, 2026, Nasdaq notified the Company that it had regained compliance with the Minimum Stockholders’ Equity Requirement, subject to Nasdaq’s continued monitoring, and that if the Company fails to evidence compliance upon the filing of its next periodic report, it may be subject to delisting. The Company’s continued compliance depends on the SOD Transaction and its accounting. If Nasdaq or the Company’s independent registered public accounting firm reaches conclusions about the accounting for the SOD Transaction that differ from the Company’s expectations, or if the Company’s stockholders’ equity later falls below $2.5 million, Nasdaq could issue a delisting determination. See the next risk factor regarding the listing of the Company’s common stock on Nasdaq.
| 38 |
The Company’s common stock may be delisted from The Nasdaq Capital Market, including on short notice if its closing bid price remains at or below $0.10 per share for ten consecutive business days, which would reduce the liquidity and market price of the common stock and make it harder for the Company to raise capital.
The Company’s common stock is listed on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires a minimum closing bid price of $1.00 per share (the “Minimum Bid Requirement”). On June 5, 2026, Nasdaq notified the Company that, based on the closing bid price of the common stock from April 23, 2026 through June 4, 2026, the Company was no longer in compliance with the Minimum Bid Requirement. The Company has a compliance period of 180 calendar days, through December 2, 2026, to regain compliance, and as of the date of this Report it has not regained compliance. Regaining compliance requires a closing bid price of at least $1.00 for a minimum of ten consecutive business days (and Nasdaq may require a longer period). If the Company does not regain compliance by December 2, 2026, it may be eligible for a second 180-day compliance period if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, other than the minimum bid price requirement, and notifies Nasdaq of its intent to cure the deficiency. Some of those initial listing standards are more demanding than the continued listing standards that apply to the Company today. There can be no assurance that the Company will regain compliance or that Nasdaq will grant a second compliance period.
In addition, Nasdaq Listing Rule 5810(c)(3)(A)(iii) provides that a failure to meet the Minimum Bid Requirement exists if a company’s security has a closing bid price of $0.10 or less for ten consecutive business days. When that occurs, Nasdaq’s Listing Qualifications Department must issue a Staff Delisting Determination, the security is suspended from trading on Nasdaq, and the company is not eligible for any compliance period, including the compliance period the Company currently has through December 2, 2026. Under Nasdaq Listing Rule 5815(a)(1)(B)(ii)e., a timely request for a hearing before a Nasdaq Hearings Panel does not stay that suspension, so the common stock would generally be expected to trade in the over-the-counter market while the Hearings Panel considers the matter. The Hearings Panel may, but is not required to, allow up to 180 days from the date of the Staff Delisting Determination for the Company to regain compliance.
The closing sale price of the common stock on Nasdaq was below $0.10 per share on each of the six trading days from November 6, 2026 through November 13, 2026, and was $0.098 on November 13, 2026. Nasdaq applies this rule using the closing bid price, which can differ from the closing sale price. If the closing bid price remains at or below $0.10 for ten consecutive business days, Nasdaq will issue a Staff Delisting Determination and suspend trading in the common stock, which could occur before the Company’s annual meeting on December 2, 2026 and before the Company could effect a reverse stock split. If the closing bid price was also at or below $0.10 on each of those days, the tenth consecutive business day would be November 19, 2026. The Company cannot predict whether the price of the common stock will rise above $0.10 or whether it will remain above that level.
The Company has asked its stockholders to approve, at the December 2, 2026 annual meeting, an amendment to its certificate of incorporation to permit a reverse stock split of the common stock at a ratio in the range of 1-for-20 to 1-for-40, with the ratio and timing to be set by the Board of Directors, which may abandon the amendment. Stockholders may not approve the proposal, and the Board may not complete a reverse stock split in time to prevent a delisting determination. Even if a reverse stock split is completed, the market price of the common stock may not rise in proportion to the split ratio, may not stay at or above $1.00 for the ten consecutive business days Nasdaq requires, and may decline afterward. A reverse stock split would also reduce the number of shares outstanding (a 1-for-40 split would leave approximately 840,235 shares outstanding, based on the shares outstanding on the October 9, 2026 record date), and under Nasdaq Listing Rule 5810(c)(3)(A) a company is not considered to have regained compliance with the Minimum Bid Requirement if the action it takes to do so causes its security to fall below the numeric threshold for another listing requirement, such as the minimum number of publicly held shares or public holders.
Nasdaq’s rules also limit the time available after a reverse stock split. Under Nasdaq Listing Rule 5810(c)(3)(A)(iv), if a company’s security fails to meet the minimum bid price requirement and the company has effected a reverse stock split over the prior one-year period, or one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one, the company is not eligible for any compliance period and Nasdaq must issue a Staff Delisting Determination. The Company’s most recent reverse stock split was a 1-for-25 split effective October 25, 2023. If the Company effects a reverse stock split and its common stock again falls below $1.00 within the following year, Nasdaq would not provide a compliance period and would issue a Staff Delisting Determination, although the Company could request review by a Hearings Panel. Additional reverse stock splits within a two-year period could also cause the cumulative ratio to reach 250-to-1 or more, which would have the same result.
The Company must also meet Nasdaq’s other continued listing requirements, including the Minimum Stockholders’ Equity Requirement discussed in the preceding risk factor. In addition, Nasdaq has adopted a new continued listing requirement that a company’s market value of listed securities be at least $5 million (Nasdaq Listing Rule 5550(a)(6)). The approval of that rule by the Securities and Exchange Commission’s staff on July 22, 2026 has been stayed pending Commission review (on September 11, 2026, the Commission granted petitions for review and continued the stay), and Nasdaq has stated that the rule will become operative only when the stay is terminated. If the rule takes effect, a company whose market value of listed securities stays below $5 million for 30 consecutive business days will receive a Staff Delisting Determination, and a hearing request will not stay the suspension of its securities from trading. Based on the closing sale price on November 13, 2026 and the 33,820,768 shares outstanding at September 30, 2026, the market value of the Company’s common stock was approximately $3.3 million (the Company has issued additional shares since September 30, 2026).
| 39 |
If the common stock is delisted from Nasdaq, it would likely trade on the over-the-counter market, where it would likely be less liquid and more volatile. Delisting would likely reduce the market price of the common stock, make it more difficult for stockholders to buy or sell shares, reduce the Company’s ability to raise capital, limit analyst and institutional investor interest in the common stock, and harm the Company’s reputation. The common stock could also become subject to the SEC’s “penny stock” rules, which require broker-dealers to follow additional disclosure and sales practices before selling the common stock and could further reduce trading in it. Under the Note Purchase Agreement with Streeterville (Section 4), the Company must keep its common stock listed or quoted on Nasdaq, the NYSE or NYSE American, must not allow trading in the common stock to be suspended for more than three full trading days, and must file its SEC reports on time. Under Section 5.1(g) of the Note, a failure to meet these covenants is an Event of Default with no cure period. Streeterville could then accelerate the Note and charge default interest of 22% per year. There can be no assurance that the Company will regain or maintain compliance with Nasdaq’s listing requirements.
In 2025 and 2026, the Company worked to pivot its sales, marketing distribution model, including via the acquisition of the Sleep Center of Nevada (the “Acquisition”). However, this new model is unproven and may not produce the benefits the Company anticipates. This makes it difficult to evaluate the Company’s future prospects and may increase the risk of your investment.
In June 2025, the Company acquired all assets, including operating assets such as sleep testing, diagnostics, and treatment centers, of SCN. The Acquisition marked the completion in a pivot to the Company’s sales, marketing and distribution model for the Company’s innovative OSA appliances. Under the new model, SCN will provide sleep disorder patients with the opportunity to be candidates for the Company’s advanced, proprietary and FDA-cleared CARE oral medical devices, oral appliances and additional adjunctive therapies and methods. Under customary agreements designed to comply with applicable corporate practice of medicine law, the Company’s operation of SCN allows the Company to manage and capture both diagnostic and consulting revenues, representing new higher margin revenue streams for the Company, as well as potential Vivos appliance sales revenue from SCN. The Company is exploring and seeking to implement additional acquisitions of, or collaborations with, medical sleep and similar healthcare practices to expand the Company’s business model in an effort to grow the Company’s revenues.
The Company is placing significant emphasis on establishing and growing this new model as means of increasing the Company’s revenue. However, this new model is unproven, and the Company has limited operating history associated with this new model. The Company’s prior collaboration with Rebis Health in Colorado entered into in 2024 has not met the Company’s expectations and differed materially from the SCN acquisition in that the Company did not have adequate control over patient processing, systems and protocols, dentist hiring and management, staff hiring and management, patient education, hours of operation, or medical provider training and education. As a result, the Rebis Health collaboration has not benefited the Company as the Company had anticipated. There is therefore a lack of information for you to evaluate the Company’s future prospects utilizing this new model. Moreover, there is a material risk that this new model will not increase the Company’s revenues or gross margins in the manner the Company anticipates. In addition, the Company may be unable to find additional sleep medical providers to incorporate into the Company’s business, and even if the Company does, there is a risk the Company may not derive the benefits from additional acquisitions that the Company intends to. The Company’s inability to implement and scale this marketing and distribution model would materially harm the Company’s business and operating results and likely cause the Company’s stock price to suffer.
Additionally, if the benefits of the Acquisition or similar acquisitions or collaborations the Company may undertake do not meet the expectations of its shareholders, the market price of the Company’s securities may decline. Fluctuations, including declines, in the price of the Company’s common stock could contribute to the loss of all or part of your investment. Certain factors, including, but not limited to, the factors listed below could have a material adverse effect on the price of the Company’s common stock:
| ● | actual or anticipated fluctuations in financial results post-Acquisition or following the execution of similar transactions; | |
| ● | changes in the market’s expectations about the Company’s operating results post-Acquisition or following the execution of similar transactions; | |
| ● | announcements of technological innovation, or new products, by the Company’s competition; and | |
| ● | the success of the Company’s competitors. |
| 40 |
As such, no assurances can be given that the Acquisition or similar transactions will benefit the Company’s operating results or stock price.
The Company has incurred substantial indebtedness in connection with financing the SCN acquisition, and the cost of servicing that debt could adversely affect the Company’s business, financial condition, and results of operation, and the Company may not be able to service that debt in the future.
Concurrently with the SCN Acquisition, the Company entered into a Note Purchase Agreement with Streeterville Capital, LLC, a Utah limited liability company (“Streeterville” or “Lender”), pursuant to which the Company issued and sold to Lender a Secured Promissory Note in the original principal amount of $8,225,000 (the “Note”). The Note is secured by the Company’s wholly-owned subsidiary AIM, which manages SCN in accordance with the corporate practice of medicine. The Company has also pledged the entirety of AIM’s membership interests to the Lender as collateral for the Note and caused AIM to provide a guarantee of the Company’s obligations to the Lender under the Note and the other transaction documents.
In June 2026, the Company entered into an Exchange Agreement with Streeterville under which Streeterville agreed to exchange a portion of the outstanding indebtedness under the Note for shares of the Company’s preferred stock and common stock, contingent on the Company’s completion of a qualifying financing of at least $2.6 million. In August 2026, the financing condition was satisfied. On August 4, 2026, Streeterville exchanged $3,250,000 of principal of the Note for 1,812,031 shares of common stock and 2,500 shares of Series B Non-Convertible Preferred Stock, and on September 2, 2026 it exchanged a further $2,861,270 of principal for up to 11,445,080 shares of common stock. In connection with the Exchange Agreement, the Note was amended on June 5, 2026 (as modified by a letter agreement dated June 18, 2026) to extend the maturity date to June 10, 2027, suspend Streeterville’s monthly redemption requests until September 15, 2026, and reduce the maximum monthly redemption amount from $550,000 to $225,000. Interest on the Note accrues at 9% per year, and a monitoring fee of about 17.6% of the outstanding balance has been added to the balance since October 7, 2025. See Note 9 to the accompanying financial statements for additional information. Notwithstanding the exchange, a portion of the original Note remains outstanding and continues to be secured by the collateral and guarantees described above. As of September 2, 2026, the outstanding principal balance of the Note was approximately $3.7 million, as reported in the Company’s Current Report on Form 8-K/A filed September 8, 2026. The principal balance at September 30, 2026 is $2.3 million. In addition, Series B Non-Convertible Preferred Stock issued in the exchange carries preferential rights (including with respect to dividends, liquidation, and other terms) that rank senior to the Company’s common stock, resulted in dilution to existing common stockholders, and makes the Company subject to certain affirmative and negative covenants in favor of Streeterville, including a requirement that the Company obtains Streeterville’s consent for future debt and equity financings over $2.5 million in the aggregate, which may restrict the Company’s ability to access capital or require the Company to access capital on terms that are not as favorable as would otherwise have been available. The Note Purchase Agreement also requires the Company to keep its common stock listed on a national securities exchange, and a failure to do so is an Event of Default with no cure period. See the risk factor below regarding the listing of the Company’s common stock on Nasdaq.
The Company’s ability to make scheduled payments under the Note or any alternative debt financing arrangements the Company may enter into in connection with its growth strategy to acquire additional medical sleep practices will depend on the Company’s financial and operating performance, which will be affected by economic, financial, competitive, business, and other factors, some or all of which are beyond the Company’s control. The indebtedness the Company incurred in connection with the Acquisition will require the Company to dedicate a portion of the Company’s cash flow to servicing this debt, thereby reducing the availability of cash to fund other business initiatives. There can be no assurance that the Company’s business, inclusive of SCN, will generate sufficient cash flow from operations to service the Company’s indebtedness or to fund the Company’s other liquidity needs. If the Company is unable to meet its debt obligations or fund its other liquidity needs, the Company may need to restructure or refinance all or a portion of its indebtedness on or before maturity, which is June 10, 2027, or sell certain of the Company’s assets. As described in Note 2 to the accompanying condensed consolidated financial statements, there is substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be able to restructure or refinance any of its indebtedness on commercially reasonable terms, if at all, which could cause the Company to default on the Company’s debt obligations and impair the Company’s liquidity. Any refinancing of the Company’s indebtedness could be at higher interest rates and may require the Company to comply with more onerous covenants, which could further restrict the Company’s business operations. If the Company is unable to generate or borrow sufficient cash to make payments on the Company’s indebtedness, the Company’s business, financial condition, and results of operations could be adversely affected.
Integrating SCN’s operations may be more difficult, costly, or time-consuming than expected.
The ongoing integration of Vivos and SCN could result in the disruption of the Company’s ongoing business, and inconsistencies in standards, controls, procedures and policies that adversely affect the Company’s ability to maintain relationships with patients and employees or achieve the anticipated benefits of the Acquisition. As with any acquisition, there also may be disruptions that cause the Company to lose patients or cause patients to elect alternative form of sleep treatment. The Company may also face other unintended consequences from the Acquisition (including adverse effects on the Company’s business reputation, supply chain issues, and similar matters) that could have a material adverse effect on the Company’s results of operations, financial condition and stock price.
| 41 |
If the Company’s contractual arrangements between AIM and the Company’s physicians at SCN are found to constitute the improper rendering of medical services or fee splitting under applicable state laws, the Company’s business, financial condition and the Company’s ability to operate in those states could be adversely impacted.
The Company’s contractual relationships between AIM and the Company’s physicians at SCN (and similar arrangements the Company may enter into in the future in connection with other sleep provider acquisitions) may implicate certain state laws that generally prohibit non-professional entities from providing licensed medical services or exercising control over medical practitioners or other healthcare professionals (such activities generally referred to as the “corporate practice of medicine”, and laws, rules and regulations relating to the corporate practice of medicine, the “CPM Laws”) or engaging in certain practices such as fee-splitting with such licensed professionals. The interpretation and enforcement of CPM Laws vary significantly from state to state. There can be no assurance that CPM Laws will be interpreted in a manner consistent with the Company’s practices or that other laws or regulations will not be enacted in the future that could have a material and adverse effect on the Company’s business, financial condition and results of operations. Regulatory authorities, state boards of medicine, state attorneys general and other parties may assert that, despite the agreements through which the Company operates, the Company is engaged in the provision of medical services and/or that its arrangements with the Company’s medical practitioners constitute unlawful fee-splitting. If a jurisdiction’s prohibition on the corporate practice of medicine or fee-splitting is interpreted in a manner that is inconsistent with the Company’s practices, the Company would be required to restructure or terminate its arrangements with the Company’s medical practitioner at SCN to bring the Company’s activities into compliance with such CPM Laws. A determination of non-compliance, or the termination of or failure to successfully restructure these relationships could result in disciplinary action, penalties, damages, fines, and/or a loss of revenue, any of which could have a material and adverse effect on the Company’s business, financial condition and results of operations. State corporate practice and fee-splitting prohibitions also often impose penalties on the Company’s medical practitioners for aiding in the improper rendering of professional services, which could discourage medical practitioners and other healthcare professionals from providing clinical services at SCN or other sleep centers the Company may operate in the future.
As a result of the Company’s business model pivot which includes the acquisition of sleep centers like SCN, the Company may become a party to lawsuits, demands, claims, qui tam suits, governmental investigations and audits and other legal matters, any of which could result in, among other things, substantial financial and other penalties, damage to the Company’s reputation or adverse effects on the Company’s ability to conduct business.
As a result of the Company’s 2025 business model pivot, which includes acquisitions of sleep medical providers like SCN as a means of driving sales of the Company’s OSA treatments, the Company’s business has (subject to compliance with CPM laws as described above) become more associated with diagnosing and treating OSA patients. Given the nature of this business, the Company may in the future be subject to investigations and audits by governmental agencies, private civil qui tam complaints and other lawsuits, demands, claims, legal proceedings and/or other actions alleging the Company’s, or the medical practices the Company manages, failure to comply with applicable rules, regulations, laws or the practice of medicine.
For example, the Company and sleep medical providers the Company manages (like SCN) could become subject to audits from the government concerning the billing of patients. If, following the conclusion of any audit, the government were to require refunds and/or modifications to the Company’s business practices, and such amounts or changes are significant, it could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. In addition, any allegation against the Company, the Company’s medical providers the Company manages or related personnel, representatives, third party vendors, or operations in such matters or matters that involve patients suffering adverse health outcomes, may, among other things harm the Company’s reputation, stock price, and adversely affect the Company’s relationships and/or contracts related to the Company’s business, among other things.
Responding to subpoenas, investigations and other lawsuits, claims and legal proceedings, as well as defending itself in such matters, would require management’s attention and cause the Company to incur significant legal expense. Negative developments, findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future legal or regulatory matters, or have been forced upon the Company, could result in, among other things, harm to the Company’s or the Company’s medical providers’ reputation, substantial financial penalties or awards against the Company, substantial payments made by the Company, required changes to the Company’s business practices, impacts on the Company’s various relationships and/or contracts related to the Company’s business, exclusion from future participation in Medicare, Medicaid and other healthcare programs and, in certain cases, criminal penalties, any of which could have a material adverse effect on the Company.
| 42 |
Changes in the structure of and payment rates under private insurance, Medicare, Medicaid or other non-Medicare government-based programs or payment rates related to the Company’s business could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows.
Sleep center providers like SCN or other medical sleep providers the Company may acquire and manage or do business with rely on various forms of insurance held by patients for payment for products and services. These include private insurance, Medicare, Medicaid and other government programs. As such, the business of the medical sleep providers the Company manages and its business and results of operations could be adversely impacted by matters related to insurance coverage including, without limitation:
| ● | The risk that reimbursement rates are reduced by private insurance carriers or government insurance providers; |
| ● | The risk that changes in insurance policies or regulatory mandates could limit the ability to either be paid for covered services or bill for treatments or services or otherwise impact reimbursement; |
| ● | The risk that interpretations of existing regulations, manual provisions and/or guidance, or the implementation or enforcement of new interpretations, will be inconsistent with how the Company and the medical sleep providers the Company manages have interpreted regulations, manual provisions and/or guidance; |
| ● | The risk that data and related reporting requirements are implemented that result in decreased reimbursement, increased technology and operational costs, or reputational harm; |
| ● | The risk that increases in the Company’s operating costs will outpace any Medicare or other rate increases the Company receives; |
| ● | The risk of federal budget sequestration cuts or other disruptions in federal government operations and funding; and |
| ● | The risk of ensuring that the sleep medical providers the Company manages remain compliant with applicable requirements, including marketing and education requirements and restrictions, as well as contractual terms with associated insurance plans. |
If the Company is faced with these or similar risks, the Company could face material adverse consequences on its business, results of operations, financial condition and cash flows.
The Company’s business and the medical practices the Company manages are labor intensive. The Company’s inability to recruit qualified talent and manage labor costs or shortages could result in significant increases in the Company’s operating costs, decreases in productivity, and disruptions in the Company’s business operations.
The Company’s business and the business of the medical practices the Company manages is labor intensive. This is particularly true with respect to the Sleep Optimization (SO) teams the Company is putting in place at SCN, each consisting of one nurse practitioner (or physician’s assistant), two specially trained dentists, six dental assistants, six administrative support personnel, and one treatment navigator. Labor requirements also exist, albeit to a lesser extent, for contractual alliances with medical sleep providers the Company may enter into. The Company faces increased labor costs and the risk of difficulties in hiring skilled clinical personnel. The healthcare labor market for the talent the Company requires is challenging and experiences volatility, uncertainty and labor supply shortages. The Company may be unable to achieve the financial results the Company desires from the SCN acquisition, the acquisition of other medical sleep providers or the Company’s contractual alliances due to variations in labor-related costs and the productivity of the Company’s personnel.
| 43 |
The Company has incurred and, as the Company seeks to scale its business, expects to continue to incur increased labor costs, including through elevated compensation levels to the Company’s personnel, the ultimate extent of which will depend on the needs at SCN or other medical sleep providers the Company acquires as well as macroeconomic conditions and ancillary impacts on the labor market, among other things.
The Company competes for qualified talent with hospitals and other healthcare providers. Furthermore, changes in certification requirements could adversely impact the Company’s ability to maintain sufficient staff levels, including to the extent the Company’s personnel are not able to meet new requirements. In addition, if the Company experiences a higher than normal turnover rate for its skilled clinical personnel, the Company’s operations and ability to meet patient demand may be negatively impacted, which could adversely affect the Company’s business, results of operations, financial condition and cash flows.
Also, political or other efforts at the national or local level could result in actions or proposals that increase the likelihood of success of union organizing activities at the facilities the Company manages. If a significant portion of the Company’s personnel were to become unionized, the Company could experience, among other things, potential additional work stoppages or other business disruptions; adverse impacts to the Company’s financial results due to the costs of bargaining or implementing a grievance procedure and processing grievances, decreases in the Company’s operational flexibility and efficiency, or negative impacts on the Company’s employee culture. Any of these events or circumstances, including the Company’s responses to such events or circumstances, could have a material adverse effect on the Company’s employee relations, treatment growth, productivity, business, results of operations, financial condition, cash flows and reputation.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None, except as otherwise included in a Current Report on Form 8-K filed with the SEC. In addition, during the three months ended September 30, 2026, the Company issued 312,500 shares of common stock to consultants as compensation for services without registration under the Securities Act of 1933 in reliance on the exemption under Section 4(a)(2) thereof.
On August 4, 2026, the Company issued 1,812,031 shares of common stock and 2,500 shares of Series B Non-Convertible Preferred Stock to Streeterville Capital, LLC in exchange for $3,250,000 of principal of the Company’s secured promissory note held by Streeterville Capital, LLC under the Exchange Agreement dated June 5, 2026. On September 2, 2026, under twelve exchange agreements dated as of August 31, 2026, the Company issued an aggregate of 11,445,080 shares of common stock to Streeterville Capital, LLC in exchange for a further $2,861,270 of principal of that note, which was partitioned into twelve separate notes that Streeterville Capital, LLC surrendered for cancellation when the related shares became freely tradable. The Company received no proceeds from these exchanges. These securities were issued without registration under the Securities Act of 1933 in reliance on the exemption provided by Section 3(a)(9) thereof.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
None.
Item 6. Exhibits, Financial Statement Schedules.
The following documents are filed , furnished or incorporated by reference as exhibits to this Quarterly Report on Form 10-Q.
| Exhibit No. | Exhibit Description | |
| 3.1 | Certificate of Incorporation of Vivos Therapeutics, Inc. filed with Delaware Secretary of State on August 12, 2020. (1) | |
| 3.2 | Amended and Restated Bylaws of Vivos Therapeutics, Inc. (1) | |
| 3.3 | Certificate of Conversion filed with Delaware Secretary of State on August 12, 2020. (1) | |
| 3.4 | Certificate of Amendment to the Certificate of Incorporation of Vivos Therapeutics, Inc., dated October 25, 2023. (2) | |
| 3.5 | Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, filed with the Secretary of State of the State of Delaware on July 7, 2026. (3) | |
| 3.6 | Certificate of Designations of Series C Convertible Preferred Stock of Vivos Therapeutics, Inc., filed with the Secretary of State of the State of Delaware on October 15, 2026. (10) | |
| 3.7 | Form of Certificate of Designation of Preferences and Rights of Series B Non-Convertible Preferred Stock (filed as Exhibit A to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 8, 2026). (4) |
| 44 |
| 4.1 | Form of Common Stock Purchase Warrant, dated June 30, 2026, issued in connection with the Securities Purchase Agreement dated June 30, 2026. (3) | |
| 4.2 | Registration Rights Agreement, dated June 30, 2026, by and among the Company, V-Co Investors 4 LLC and Bigger Capital Fund, LP. (3) | |
| 10.1 | Exchange Agreement, dated June 5, 2026, by and between the Company and Streeterville Capital, LLC. (4) | |
| 10.2 | Letter Agreement, dated June 18, 2026, by and between the Company and Streeterville Capital, LLC, amending the Exchange Agreement dated June 5, 2026. (5) | |
| 10.3 | Securities Purchase Agreement, dated June 30, 2026, by and among the Company, V-Co Investors 4 LLC and Bigger Capital Fund, LP. (3) | |
| 10.4# | Master Services Agreement, dated July 31, 2026, by and between the Company and The CFO Portal, LLC. (6) | |
| 10.5# | Separation, Resignation and Executive Transition Agreement, dated July 31, 2026, by and between the Company and Bradford Amman. (6) | |
| 10.6 | Form of Exchange Agreement, effective as of August 31, 2026, by and between the Company and Streeterville Capital, LLC. (7) | |
| 10.7 | Collaboration Agreement, dated as of June 9, 2026, by and between the Company and South Palm Cardiovascular Associates, LLC. (8) | |
| 10.8 | Mutual Stock Purchase and Asset Exchange Agreement, dated as of October 14, 2026, by and between the Company and SOD Sciences, Inc.† (9) | |
| 10.9 | First Amendment to Mutual Stock Purchase and Asset Exchange Agreement, dated as of October 15, 2026, by and between the Company and SOD Sciences, Inc. (10) | |
| 10.10 | Amendment No. 2 to Mutual Stock Purchase and Asset Exchange Agreement, dated as of October 16, 2026, by and between the Company and SOD Sciences, Inc. (10) | |
| 10.11 | Assignment and Co-Ownership Agreement (Test Interest), dated as of October 16, 2026, by and between SOD Sciences, Inc. and the Company† (10) | |
| 31.1* | Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| 31.2* | Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| 32.1** | Certification of the Chief Executive Officer pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 32.2** | Certification of the Chief Financial Officer pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 101.INS* | Inline XBRL Instance Document | |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema | |
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase | |
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase | |
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase | |
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
| * | Filed herewith. | |
| ** | Furnished herewith. | |
| # | Management contract or compensatory plan or arrangement. | |
| † | Certain schedules (and exhibits) have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request. |
| (1) | Incorporated by reference to the Company’s Registration Statement on Form S-1, filed with the SEC on October 9, 2020. |
| (2) | Incorporated by reference to the Company’s Current Report on Form 8-K, filed with the SEC on October 27, 2023. |
| (3) | Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on July 7, 2026. |
| (4) | Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on June 8, 2026. The form of certificate filed as Exhibit A to Exhibit 10.1 was erroneously titled “Series A Preferred Stock,” but it is the form of Certificate of Designation for the Series B Non-Convertible Preferred Stock. |
| (5) | Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on June 25, 2026. |
| (6) | Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on August 3, 2026. |
| (7) | Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on September 8, 2026. |
| (8) | Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on June 16, 2026. |
| (9) | Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on October 15, 2026. |
| (10) | Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on October 19, 2026. |
| 45 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Vivos Therapeutics, Inc. | ||
| Date: November 16, 2026 | By: | /s/ R. Kirk Huntsman |
| R. Kirk Huntsman | ||
| Chairman of the Board and Chief Executive Officer | ||
| (principal executive officer) | ||
| Date: November 16, 2026 | By: | /s/ Roman Franklin |
| Roman Franklin | ||
| Chief Financial Officer | ||
| (principal financial officer) | ||
| 46 |